Updates on possible LAST-MINUTE CHANGES of Business Meeting schedules and chairpersons can be found on the congress website:

www.eaneurology.org/berlin2015
# TABLE OF CONTENTS

## GENERAL

Co-sponsorship .......................................................... II
Welcoming words .......................................................... IV
About Berlin .............................................................. VI
Committees ............................................................... VII
Appreciation and thanks ............................................. IX
Acknowledgements .................................................... XII
CME accreditation ........................................................ XVI
General information ..................................................... XVII
Overview of business meetings ...................................... XXIV
Caring for the environment ............................................ XIX
Poster Session overview .............................................. XXVII
Networking Programme ............................................... XXXVIII
Timetable ................................................................. XLII
Hall Plan ................................................................. XLVI

## SCIENTIFIC PROGRAMME

### SATURDAY, JUNE 20, 2015

<table>
<thead>
<tr>
<th>Event</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symposia</td>
<td>53</td>
</tr>
<tr>
<td>Focused Workshops</td>
<td>56</td>
</tr>
<tr>
<td>Interactive Session</td>
<td>64</td>
</tr>
<tr>
<td>Hands-on course</td>
<td>65</td>
</tr>
<tr>
<td>Oral Session</td>
<td>66</td>
</tr>
<tr>
<td>Teaching Courses</td>
<td>79</td>
</tr>
</tbody>
</table>

### SUNDAY, JUNE 21, 2015

<table>
<thead>
<tr>
<th>Event</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hands-on course</td>
<td>87</td>
</tr>
<tr>
<td>Plenary Symposium</td>
<td>88</td>
</tr>
<tr>
<td>Focused Workshops</td>
<td>89</td>
</tr>
<tr>
<td>Interactive Session</td>
<td>97</td>
</tr>
<tr>
<td>Tournament</td>
<td>99</td>
</tr>
<tr>
<td>Oral Session</td>
<td>100</td>
</tr>
<tr>
<td>Teaching Courses</td>
<td>111</td>
</tr>
<tr>
<td>Scientific Satellite Symposia</td>
<td>117</td>
</tr>
</tbody>
</table>

### MONDAY, JUNE 22, 2015

<table>
<thead>
<tr>
<th>Event</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hands-on course</td>
<td>121</td>
</tr>
<tr>
<td>Symposia</td>
<td>122</td>
</tr>
<tr>
<td>Focused Workshops</td>
<td>125</td>
</tr>
<tr>
<td>Interactive Session</td>
<td>132</td>
</tr>
<tr>
<td>Special Session</td>
<td>134</td>
</tr>
<tr>
<td>Tournament</td>
<td>135</td>
</tr>
<tr>
<td>Oral Session</td>
<td>136</td>
</tr>
<tr>
<td>Late Braking News</td>
<td>143</td>
</tr>
<tr>
<td>Teaching Courses</td>
<td>144</td>
</tr>
</tbody>
</table>

### TUESDAY, JUNE 23, 2015

<table>
<thead>
<tr>
<th>Event</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symposia</td>
<td>153</td>
</tr>
<tr>
<td>Special Session</td>
<td>155</td>
</tr>
<tr>
<td>Teaching Courses</td>
<td>159</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Event</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Satellite Symposia</td>
<td>167</td>
</tr>
</tbody>
</table>

Index of authors ............... 187
DEAR PARTICIPANT OF THE 1ST CONGRESS OF THE EUROPEAN ACADEMY OF NEUROLOGY,

On behalf of the European Academy of Neurology and the German Society of Neurology we are pleased to welcome you to the 1st Congress of the European Academy of Neurology (EAN). The Academy has chosen Berlin for many reasons. It is one of the world’s most vibrant capitals, with an impressive cultural, scientific and economic scene, attracting politicians and business travellers, start-ups and artists, tourists and connoisseurs from around the globe. The city is also emerging as the centre of German healthcare.

Berlin has a long neurological history. It was here that Moritz Heinrich Romberg wrote the ‘Lehrbuch der Nervenkrankheiten des Menschen’, a frontier breaking mid-19th century textbook which is seen as the foundation of modern neurology. Almost 25 years after the fall of the wall, the once divided city of Berlin today symbolizes peaceful revolution, the overthrow of outworn systems and the venture into a new political era. The 1st Congress of the EAN will also write European neurological history. EAN is the joint subsequent organisation of the EFNS (European Federation of Neurological Societies) and ENS (European Neurological Society), and thereby the first united voice of European Neurology. This founding act was celebrated on June 3rd, 2014 at the Joint Congress of European Neurology in Istanbul. The first congress of this new Society will be celebrated in the united Berlin.
WELCOMING WORDS

2015

We have a record number of pre-registrations and more than 2000 submitted abstracts. We will have 8 symposia, 33 teaching courses and overall 250 lectures and 300 speakers. The city cube will be an ideal place to discuss new developments, exchange practice hints from all over Europe and finally meet friends.

The EAN Congress in Berlin will provide the ideal platform for continuing education in all fields of neurology, covering a broad spectrum of topics with state-of-the-art lectures by renowned experts. The EAN is dedicated to providing the highest quality of continuing medical education and to opening professional education opportunities.

We are deeply grateful to the joint Programme Committee and its chairpersons Jacques L. De Reuck and Gustave Moonen and the new programme committee with the chair Paul Boon and the many people helping us to organise this major event.

We are looking forward to welcoming you to Berlin in 2015!

Sincerely yours,

Günther Deuschl
President of the European Academy of Neurology

Wolfgang H. Oertel
Past President German Society of Neurology

PRESIDENT OF THE EUROPEAN ACADEMY OF NEUROLOGY
LOCAL CONVENOR
PAST PRESIDENT GERMAN SOCIETY OF NEUROLOGY
ABOUT BERLIN

Berlin, the capital of Germany, represents with its population of 3.4 million people Germany’s largest city. It is located in north-eastern Germany on the river Spree and is the centre of the Berlin-Brandenburg metropolitan region. Due to its location in the European plain, Berlin is influenced by a temperate seasonal climate. About one third of the city’s area consists of forests, gardens, parks, rivers and lakes.

The city has been an imperial capital of the Kingdom of Prussia, the German Empire, the Weimar Republic and the Third Reich. After World War II, the city, along with the German state, was divided into East Berlin and West Berlin, (surrounded by the Berlin Wall from 1961 to 1989). After the German reunification in 1990, Berlin was again designated as the capital of all Germany.

Berlin is a world city of culture, science, media and politics and is hosting 147 foreign embassies. The city is also well known for its renowned universities, research institutes, orchestras, operas, museums, and celebrities; as well as for its festivals, diverse architecture, nightlife, contemporary arts, public transportation networks, and an extremely high quality of living.
COMMITTEES

BOARD

PRESIDENT Günther Deuschl, GERMANY
VICE PRESIDENTS Franz Fazekas, AUSTRIA
SECRETARY GENERAL Didier Leys, FRANCE
TREASURER Marianne de Visser, THE NETHERLANDS
MEMBER AT LARGE Per Soelberg Sörensen, DENMARK

CHAIR EDUCATION COMMITTEE Hannah R. Cock, UK
CHAIR LIAISON COMMITTEE David B. Vodušek, SLOVENIA
CHAIR PROGRAMME COMMITTEE Paul Boon, BELGIUM
CHAIR SCIENTIFIC COMMITTEE Antonio Federico, ITALY

PROGRAMME COMMITTEE

CHAIRPERSON Paul Boon, BELGIUM
CO-CHAIRPERSON Wolfgang Oertel, GERMANY
MEMBERS Ljiljana Beslac-Bumbasirevic, SERBIA
Valeria Caso, ITALY
Marianne Dieterich, GERMANY
Theodor Landis, SWITZERLAND
Philip Scheltens, THE NETHERLANDS
Aksel Siva, TURKEY
Riccardo Soffietti, ITALY
Guido Stoll, GERMANY

TEACHING COURSE SUB-COMMITTEE Theodor Landis, SWITZERLAND
See You In Vienna

Mechanisms, Clinical Strategies, and Promising Treatments of Neurodegenerative Diseases

AD/PD™ 2017
The 13th International Conference on Alzheimer’s & Parkinson’s Diseases
March 29 - April 2, 2017 | Vienna, Austria

ORGANIZING COMMITTEE
Abraham Fisher, Israel, President
Roger M. Nitsch, Switzerland, Executive Organizer
Manfred Windisch, Austria, Executive Organizer

adpd2017.kenes.com
THANK YOU!

We would like to thank the reviewers of the submitted abstracts for their invaluable help and assistance:

A
Sharon Abrahams, UNITED KINGDOM
Alberto Albanese, ITALY
Yuri Alekseenko, BELARUS
Maria Pia Amato, ITALY
Angelo Antonini, ITALY
Anita Arsovska, FYRO MACEDONIA
Eduard Auff, AUSTRIA

B
Anish Bahra, UNITED KINGDOM
Ronny Beer, AUSTRIA
Kailash Bhatia, UNITED KINGDOM
Laurence Bisdorff, LUXEMBOURG
Natan Bornstein, ISRAEL
Michael Brainin, AUSTRIA
Adolfo M. Bronstein, UNITED KINGDOM
Martin Brown, UNITED KINGDOM
Valmantas Budrys, LITHUANIA

C
Pasquale Calabrese, SWITZERLAND
Stefano F. Cappa, ITALY
Evelien Carrette, BELGIUM
Mamede Carvalho, PORTUGAL
Valeria Caso, ITALY
Raffaella Chieffo, ITALY
Giovanni Cirillo, ITALY

Hannah Cock, UNITED KINGDOM
Carlo Colosimo, ITALY
Giancarlo Comi, ITALY
Charlotte Cordonnier, FRANCE
László Csiba, HUNGARY

D
Maxwell Damian, UNITED KINGDOM
Marianne de Visser, THE NETHERLANDS
Günther Deuschl, GERMANY
Marianne Dieterich, GERMANY
Volker Dietz, SWITZERLAND
Marija Djukic, GERMANY

E
Mark Edwards, UNITED KINGDOM
Mikael Elam, SWEDEN
Kirsten Elwischger, AUSTRIA
Christian Enzinger, AUSTRIA

F
Cristian Falup-Pecurariu, UNITED KINGDOM
Antonio Federico, ITALY
Daniela Ferrari, ITALY
José Manuel Morão Cabral Ferro, PORTUGAL
Massimo Filippi, ITALY
Katharina Fink, SWEDEN
Sten Fredrikson, SWEDEN
APPRECIATION AND THANKS

2015

G
Franz Gerstenbrand, AUSTRIA
Nils Erik Gilhus, NORWAY
Colette Griffin, UNITED KINGDOM
Wolfgang Grisold, AUSTRIA
Michael Guger, AUSTRIA
Orsi Győrfi, HUNGARY

H
Ellen Merete Hagen, NORWAY
Hans-Peter Hartung, GERMANY
Mirjam Heldner, SWITZERLAND
David Henshall, IRELAND
Max Hilz, GERMANY
Rigmor Højland Jensen, DENMARK
Martin Holtkamp, GERMANY

I
Alex Iranzo, SPAIN

J
Poul Jennum, DENMARK

K
L.J. Kappelle, NETHERLANDS
Alexander Karameshev, BULGARIA
Viktoria Kdzieycz, POLAND
Samson Khachatryan, ARMENIA
Thomas Klapstock, GERMANY
Wolfgang Köhler, GERMANY
Daniel Kondziella, DENMARK
Janika Kórv, ESTONIA
Jera Kruja, ALBANIA
Jan Kuks, THE NETHERLANDS

L
Theodor Landis, SWITZERLAND
Nicola Latronico, ITALY
Jean Marc Léger, FRANCE
Maurizio Leone, ITALY
Vitalie Lisnic, MOLDOVA

M
Antonella Macerollo, ITALY
Björn Machner, GERMANY
Monica Margoni, ITALY
Davide Martino, UNITED KINGDOM
Christopher Mathias, UNITED KINGDOM
Edgar Meinl, GERMANY
Ioannis Milonas, GREECE
Antonija Mišmaš, CROATIA
Monica Moarcas, UNITED KINGDOM
Xavier Montalban, SPAIN
Lucia Muntean, GERMANY

N
Bo Norrving, SWEDEN

O
Jes Olesen, DENMARK
Józef Opara, POLAND
Celia Oreja-Guevara, SPAIN

P
Cristina Panea, ROMANIA
Eleftherios Papathanasiou, CYPRUS
Fabienne Perren, SWITZERLAND
Daniela Pohl, CANADA
APPRECIATION AND THANKS

2015

R
Dorota Religa, SWEDEN
Martin Rossor, UNITED KINGDOM
Roberta Rudà, ITALY
Evzen Ruzicka, CZECH REPUBLIC

S
Ettore Salsano, ITALY
Anna Sauerbier, UNITED KINGDOM
Reinhold Schmidt, AUSTRIA
Erich Schmutzhard, AUSTRIA
Benedikt Schoser, GERMANY
Johann Sellner, AUSTRIA
Vincenzo Silani, ITALY
Riccardo Soffietti, ITALY
Claudia Sommer, GERMANY
Till Sprenger, SWITZERLAND
Israel Steiner, ISRAEL
Guido Stoll, GERMANY
Walter Struhal, AUSTRIA

T
Pille Taba, ESTONIA
Marc Tardieu, FRANCE
Klaus V. Toyka, GERMANY
Maria Troiano, ITALY
Alexander Tsiskaridze, GEORGIA

V
Josep Valls-Solé, SPAIN
Edina Varga, HUNGARY
Timo Vesikari, FINLAND
Marie Vidailhet, FRANCE
Angela Vincent, UNITED KINGDOM
David Vodušek, SLOVENIA
Kristl Vonck, BELGIUM

Y
Nataliya Yavorska, UKRAINE
ACKNOWLEDGEMENTS

2015

We wish to express our gratitude to the following companies, who, through their generosity, have helped to make this Congress possible:

PREMIUM SPONSORS

[Images of company logos]

MAJOR SPONSORS

[Images of company logos]
ACKNOWLEDGEMENTS

SPONSORS

Dr. Willmar Schwabe Pharmaceuticals

Takeda

Inspired by patients. Driven by science.

Zambon

octapharma®

For the safe and optimal use of human proteins

otometrics

Pfizer
ACKNOWLEDGEMENTS

2015

WILEY

w.wisepress.com

Wolters Kluwer
The 1st Congress of the European Academy of Neurology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity (event code: 11316) for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS): http://www.uems.net.

The Joint Congress of European Neurology (Saturday, Sunday, Monday, Tuesday) is designated for a maximum of 24 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

This congress has been approved for CME by the Austrian Chamber of Physicians.

ATTENDANCE TRACKING REPORT
If you need a report of your attendance in sessions, please approach the information desk located on level 1, in order to scan your badge and record your attendance. Only participants who have recorded their attendance receive a report, tracking their daily attendance at the congress, which will be sent from the secretariat on request.
GENERAL INFORMATION

INSTRUCTIONS FOR SPEAKERS

SPEAKERS’ SERVICE CENTRE

All speakers are requested to hand in their presentations (PowerPoint only) via an USB compatible memory stick at the Speakers’ Service Centre (SSC) at least three hours before the beginning of the session. The SSC is located close to all lecture halls on Level 1.

Speakers will have the opportunity to check their presentations on PCs available in the SSC.

POSTERS

All posters will be presented as e-posters only.

Within the ePoster area (in front of the exhibition hall) there are poster screens (15 big screens & 20 computer stations) available throughout the whole congress, where presenters and audience are invited to interact with each other. You will be able to contact poster presenters and meet with them at any time at one of the poster screens to discuss his/her work.

In addition there will be two types of poster sessions, taking place Saturday - Tuesday from 12.30 - 13.15 and 13.30 - 14.15. Please see page XX for exact presentation times.

Details on the ePoster sessions can be found in the Interactive Programme Planner (IPP).

Poster with discussion

In a poster session with discussion (45 minutes) up to 9 presentations at the dedicated poster screens are scheduled. A chairperson will be present and discuss each presentation with the presenter and the audience. Each presenter will have 3 minutes presentation time and approximately 2 minutes of discussion. Please make sure that you are present at your poster screen during your session.

Flash poster
Similar to previous paper poster sessions, where presenters stood next to their posters, now all presenters (up to 20 per session) will stand at the screen; the posters will "slide by", i.e. each poster will be available for approximately 2 minutes and the presenters will have the possibility to highlight their most important data.

POSTER DESK
Technicians will be available throughout the congress in the poster area.

INFORMATION FROM A TO Z

ABSTRACTS
All accepted abstracts will be published as supplement to the European Journal of Neurology. There will be no printed book available, but a CD can be picked up at the Genzyme booth in the Exhibition Area. You can find a voucher in your congress bag. The abstracts can also be found online on www.eaneurology.org/berlin2015 and www.europeanjournalofneurology.com.

ATM/CASH MACHINE
An ATM cash machine is located on the entrance level close to the Congress Secretariat. VISA and MasterCard are accepted.

ATTENDANCE TRACKING REPORT
See page XX

BADGES
Access to all scientific events will only be possible with your personal badge, which you will receive at the self-print stations. All participants are requested to wear their name badge throughout the congress. For replacement of a lost badge EUR 30 will be charged.
GENERAL INFORMATION

BUSINESS CENTRE
There is a business centre located on the entrance level close to the Congress Secretariat.

Opening times:
- Saturday, 20 June 2015: 07.30 – 20.30 h
- Sunday, 21 June 2015: 06.30 – 19.00 h
- Monday, 22 June 2015: 06.30 – 19.00 h
- Tuesday, 23 June 2015: 07.30 – 17.30 h

CARING FOR THE ENVIRONMENT

Bag recycling – You can leave your congress bag in a designated recycling box in the registration area when leaving the congress.

Green print – The print materials of this congress have been printed on paper that is PEFC approved. The PEFC is an organisation that certifies paper manufacturers who keep to sustainable forest management criteria.

Reducing print – The book of abstracts is published on a CD Rom. The final programme is printed in a slimmer version. The complete programme can be found online (IPP). See page XX.

Recycling – As part of our efforts we try to produce less waste. We will recycle plastic, glass, cans and paper.

Offset your Carbon Footprint – You can contribute to our ecological efforts by offsetting the Carbon Footprint of your travels to Berlin. A Carbon Offset represents a reduction in emissions somewhere else. You can learn more and offset you carbon footprint at: www.carbonfund.org.

We are doing our best and there is still much to learn. We will be happy to hear your ideas; please do not hesitate to write to us at: headoffice@eaneurology.org.

LOCATION

Messe Berlin GmbH – City Cube
Messedamm 22, 14055 Berlin, Germany
Phone: +49 30 3038-0, Fax: +49 30 3038-2325
www.citycube-berlin.de
GENERAL INFORMATION

OPENING HOURS SECRETARIAT AND REGISTRATION

The registration desk at the Congress Venue is open during the following hours:

- Saturday, 20 June 2015 07.30 – 20.30 h
- Sunday, 21 June 2015 06.30 – 19.00 h
- Monday, 22 June 2015 06.30 – 19.00 h
- Tuesday, 23 June 2015 07.30 – 17.30 h

All documents included in the registration package (congress bag, personal name badge) will be handed over to the registered participants. Onsite registration will be accepted, but receipt of all congress documents cannot be guaranteed.

CERTIFICATE OF ATTENDANCE

You will receive an email with your personal login details for the online evaluation form during the evening of the last day of the congress (Tuesday, 23 June 2015). After completing the congress evaluation form you can print the certificate indicating the CME credits at home. No certificates will be handed out during the conference.

CLOAKROOM

A cloakroom is available next to the registration area and is open during the secretariat opening hours. The cloakroom service is free of charge.

EXHIBITION

An extensive exhibition will be held concurrently with the congress.

Exhibition opening hours are:

- Saturday 20 June 2015 10.00 – 17.00 h
- Sunday 21 June 2015 10.00 – 17.00 h
- Monday 22 June 2015 10.00 – 17.00 h
- Tuesday 23 June 2015 09.30 – 13.30 h

According to regulations of the Health Authorities, children under the age of 18 years will not be permitted to enter the exhibition area of the Congress.
GENERAL INFORMATION

2015

HOTEL AND TRAVEL
Travel Agency
Congrex Travel Ltd.
PHONE:  +90 212 373 99 71 (onsite)
E-MAIL:  businesstravel@congrex-switzerland.com

Congrex Travel is present at a desk during the meeting close to the Congress Secretariat. Staff can assist you with your hotel and flight bookings.

INSURANCE & LIABILITY
The Congress organisers and PCO cannot accept liability for personal accidents or loss of or damage to private property of participants, either during or indirectly arising from the 1st Congress of the European Academy of Neurology.

It is recommended that all participants are covered by personal travel insurance for their trip.

INTERNET CORNER
An internet corner is located in the exhibition area and is available to all congress participants during the opening hours of the exhibition. In this area also Wi-Fi is available.

LANGUAGE
The official language of the congress is English. No simultaneous translation will be provided.

LOST & FOUND
Please apply to the secretariat.

LUNCH AND COFFEE BREAKS
Light lunch and coffee is included in the registration fee and will be served in the exhibition area as per the times indicated in the timetable.

MAIL / MESSAGES
A message board is available close to the secretariat on the entrance level.
GENERAL INFORMATION

MEDICAL ASSISTANCE
Please apply to the information desk.

MOBILE PHONES
Please note that mobile phones must be switched off during all sessions.

POSTER SESSIONS
Please see page XX

PRESS REGISTRATION AND PRESS ROOM
A media room with wireless internet access is available to registered journalists. Press representatives must register at the secretariat showing their official press accreditation. The Press Room is located at Level 1.

QUALITY CONTROL/EVALUATION
In order to guarantee the quality of the upcoming congresses, and to get CME certification, we have to carry out congress evaluations. Each teaching course participant should fill in a TC evaluation form and hand in after the TC.

The general evaluation of the congress will be done online. On Tuesday 23 June all participants will receive a username and password per email during the evening. We kindly ask you to participate to receive your certificate.

SCIENTIFIC LOUNGE
A scientific lounge located in the exhibition area will be available for the comfort of participants, providing a place to see webcasts of selected previous sessions, relax and meet with colleagues.

SESSIONS
Please make sure to be in session halls on time as all sessions will begin as per schedule.

SMOKING POLICY
Smoking is prohibited at all times in the meeting halls, exhibit halls and restrooms. Your compliance is appreciated.
GENERAL INFORMATION

SPEAKERS SERVICE CENTRE (SSC)
See page XX

TEACHING COURSES
Please check the Scientific Programme for the scheduling of Teaching Courses. If you wish to participate, tickets may still be purchased at the Secretariat for a fee of € 40/ € 25, availability permitting.

TRAVEL
see “Hotel and Travel”

VENUE
The 1st Congress of the European Academy of Neurology takes place at the Messe Berlin – CityCube (www.citycube-berlin.de). The CityCube can be reached by several trains – get off at station “Messe Süd”. Further information can be found on the congress website and on http://www.bvg.de/index.php/en/index.html

WI-FI
Wi-Fi will be available free of charge around on Level B1 (lecture halls) and Level B2 (exhibition area).
OVERVIEW OF BUSINESS MEETINGS (in chronological order, as per date of printing)

Additional meetings reserved after the date of printing will be announced on the Message Board.

<table>
<thead>
<tr>
<th>GROUP/COMMITTEE</th>
<th>DAY, TIME</th>
<th>CITYCUBE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guideline production group meeting</td>
<td>Saturday, June 20 15:00-16:00</td>
<td>Room R8</td>
</tr>
<tr>
<td>Scientific Committee</td>
<td>Sunday, June 21 09:00-11:00</td>
<td>Room R3</td>
</tr>
<tr>
<td>Task Force Sub-Saharan Africa</td>
<td>Sunday, June 21 09:00-11:00</td>
<td>Room R1</td>
</tr>
<tr>
<td>Quality Assurance Sub-committee</td>
<td>Sunday, June 21 09:15-10:45</td>
<td>Room R5</td>
</tr>
<tr>
<td>Education Committee</td>
<td>Sunday, June 21 11:00-13:00</td>
<td>Room R5</td>
</tr>
<tr>
<td>European Journal of Neurology – Editorial Team</td>
<td>Sunday, June 21 14:00-15:00</td>
<td>TBA</td>
</tr>
<tr>
<td>European Journal of Neurology – Editorial Board</td>
<td>Sunday, June 21 15:00-16:00</td>
<td>TBA</td>
</tr>
<tr>
<td>Liaison Committee</td>
<td>Monday, June 22 09:00-11:00</td>
<td>Room R5</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel Chairs</td>
<td>Monday, June 22 11:00-13:00</td>
<td>Room M8</td>
</tr>
<tr>
<td>European Affairs Sub-committee</td>
<td>Monday, June 22 11:15-12:30</td>
<td>Room R5</td>
</tr>
<tr>
<td>Neuropenews and Website Editorial Board</td>
<td>Monday, June 22 13:00-14:30</td>
<td>Room R5</td>
</tr>
<tr>
<td>EAN/WFN Meeting</td>
<td>Monday, June 22 13:30-14:30</td>
<td>Room R3</td>
</tr>
<tr>
<td>Industrial Relations Board</td>
<td>Monday, June 22 15:00-16:30</td>
<td>Room M8</td>
</tr>
<tr>
<td>Associate Members</td>
<td>Monday, June 22 15:00-16:30</td>
<td>Room R5</td>
</tr>
<tr>
<td>Programme Committee</td>
<td>Tuesday, June 23 09:00-10:00</td>
<td>Room R5</td>
</tr>
<tr>
<td>Teaching Course sub-committee</td>
<td>Tuesday, June 23 10:30-11:30</td>
<td>Room R5</td>
</tr>
</tbody>
</table>
OVERVIEW OF BUSINESS MEETINGS

OVERVIEW OF BUSINESS MEETINGS OF SUBSPECIALTY SCIENTIFIC PANELS

TASK FORCES (in chronological order, as per date of printing)

Additional meetings reserved after the date of printing will be announced on the Message Board.

<table>
<thead>
<tr>
<th>GROUP/COMMITTEE</th>
<th>DAY, TIME</th>
<th>CITYCUBE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guideline workshop – Early Neurological Prognostication in Coma after Cardiac Arrest</td>
<td>Saturday, June 20 09.00–11.00</td>
<td>Room R8</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Autonomic nervous system disorders</td>
<td>Saturday, June 20 15.00–16.30</td>
<td>Room R3</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Neurosonology</td>
<td>Saturday, June 20 15.30–16.30</td>
<td>Room R5</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Higher cortical function</td>
<td>Saturday, June 20 15.30–16.30</td>
<td>Room R9</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Headache</td>
<td>Sunday, June 21 09.00–11.00</td>
<td>Room R6</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Neurotraumatology</td>
<td>Sunday, June 21 11.00–12.00</td>
<td>Room R8</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on ALS and frontotemporal dementia</td>
<td>Sunday, June 21 11.00–12.30</td>
<td>Room R10</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Muscle disorders</td>
<td>Sunday, June 21 11.00–13.00</td>
<td>Room R9</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Young sleep neurologists</td>
<td>Sunday, June 21 12.30–13.30 (TBC)</td>
<td>TBA</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Sleep-wake disorders</td>
<td>Sunday, June 21 15.30–16.30 (TBC)</td>
<td>TBA</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Clinical neurophysiology</td>
<td>Sunday, June 21 12.30–13.30</td>
<td>Room 3B/83</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on General neurology</td>
<td>Sunday, June 21 12.30–13.30</td>
<td>Room 3B/85</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Neurocritical care</td>
<td>Sunday, June 21 15.00–16.00</td>
<td>Room 3B/88</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Translational neurology</td>
<td>Sunday, June 21 16.00–17.00</td>
<td>Room 3B/86</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Neuro-oncology</td>
<td>Sunday, June 21 17.00–18.00</td>
<td>Room 3B/89</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Neuropathies</td>
<td>Sunday, June 21 17.30–18.30</td>
<td>Room 3B/87</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Palliative care</td>
<td>Sunday, June 21 18.15–19.15</td>
<td>Room 3B/87</td>
</tr>
</tbody>
</table>
OVERVIEW OF BUSINESS MEETINGS OF SUBSPECIALTY SCIENTIFIC PANELS, TASK FORCES (in chronological order, as per date of printing)

Additional meetings reserved after the date of printing will be announced on the Message Board.

<table>
<thead>
<tr>
<th>GROUP/COMMITTEE</th>
<th>DAY, TIME</th>
<th>CITYCUBE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subspecialty Scientific Panel on Movement disorders</td>
<td>Monday, June 22 07.00–08.00</td>
<td>Room R5 - TBC</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Neuroimaging</td>
<td>Monday, June 22 09.00–11.00</td>
<td>Room R3</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Neuro-ophthalmoology and -otology</td>
<td>Monday, June 22 09.30–10.30 (TBC)</td>
<td>TBA</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Multiple sclerosis</td>
<td>Monday, June 22 10.00–11.00</td>
<td>Room R6</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Child Neurology</td>
<td>Monday, June 22 13.00–14.00</td>
<td>Room R6</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Neurorehabilitation</td>
<td>Monday, June 22 13.00–14.00</td>
<td>Room R9</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Stroke</td>
<td>Monday, June 22 13.00–15.00</td>
<td>Room R3</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Neuroimmunology</td>
<td>Monday, June 22 13.15–14.15</td>
<td>Room R10</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Neurotoxicology</td>
<td>Monday, June 22 15.00–16.00</td>
<td>Room R3</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Dementia and cognitive disorders</td>
<td>Monday, June 22 16.00–17.00</td>
<td>Room R9</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Infectious diseases</td>
<td>Tuesday, June 23 11.00–12.00</td>
<td>Room R3</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Pain</td>
<td>Tuesday, June 23 12.00–13.00</td>
<td>Room R2</td>
</tr>
<tr>
<td>Subspecialty Scientific Panel on Neurogenetics</td>
<td>Tuesday, June 23 13.00–14.00</td>
<td>Room R3</td>
</tr>
</tbody>
</table>
Poster presenters are requested to be at their poster screen at the beginning of the sessions.

**POSTER SESSION WITH DISCUSSION: SATURDAY, JUNE 20, 2015**

<table>
<thead>
<tr>
<th>TOPIC (SCREEN NR)</th>
<th>POSTER NUMBERS</th>
<th>CHAIRS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ageing and dementia 1 (Screen A1)</td>
<td>P1101-P1108</td>
<td>Dorota Religa, SWEDEN</td>
<td>XXX</td>
</tr>
<tr>
<td>Cerebrovascular diseases 1 (Screen A3)</td>
<td>P1109-P1117</td>
<td>Monica Moarcas, ROMANIA</td>
<td>XXX</td>
</tr>
<tr>
<td>Headache and pain 1 (Screen B1)</td>
<td>P1118-P1124</td>
<td>To be announced</td>
<td>XXX</td>
</tr>
<tr>
<td>Infection and AIDS 1 (Screen B2)</td>
<td>P1125-P1132</td>
<td>Erich Schmutzhard, AUSTRIA</td>
<td>XXX</td>
</tr>
<tr>
<td>Motor neurone diseases 1 (Screen B3)</td>
<td>P1133-P1140</td>
<td>Antonia Mismas, SLOVENIA - TBC</td>
<td>XXX</td>
</tr>
<tr>
<td>Movement disorders 1 (Screen C1)</td>
<td>P1141-P1147</td>
<td>Gregor Wenning, AUSTRIA - TBC</td>
<td>XXX</td>
</tr>
<tr>
<td>Movement disorders 2 (Screen C2)</td>
<td>P1148-P1156</td>
<td>Thomas Klockgether, GERMANY</td>
<td>XXX</td>
</tr>
<tr>
<td>MS and related disorders 1 (Screen C3)</td>
<td>P1157-P1165</td>
<td>Viktoria Papp, DENMARK</td>
<td>XXX</td>
</tr>
<tr>
<td>MS and related disorders 2 (Screen C4)</td>
<td>P1166-P1174</td>
<td>To be announced</td>
<td>XXX</td>
</tr>
<tr>
<td>Neurogenetics 1 (Screen A4)</td>
<td>P1175-P1183</td>
<td>Albert Ludolph, GERMANY</td>
<td>XXX</td>
</tr>
<tr>
<td>Peripheral nerve disorders 1 (Screen A2)</td>
<td>P1184-P1192</td>
<td>Pieter van den Bergh, BELGIUM</td>
<td>XXX</td>
</tr>
</tbody>
</table>

Will be available throughout the congress on the poster screens and poster stations in front of the exhibition area. You can contact poster presenters via the Interactive Programme Planner IPP.
Poster presenters are requested to be at their poster screen at the beginning of the sessions.

**POSTER SESSION WITH DISCUSSION: SATURDAY, JUNE 20, 2015**

<table>
<thead>
<tr>
<th>TOPIC (SCREEN NR)</th>
<th>POSTER NUMBERS</th>
<th>CHAIRS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ageing and dementia 2 (Screen A1)</td>
<td>P1201-P1208</td>
<td>Agnes Pirker-Kees, AUSTRIA - TBC</td>
<td>XXX</td>
</tr>
<tr>
<td>Cerebrovascular diseases 2 (Screen A3)</td>
<td>P1209-P1217</td>
<td>Laszlo Csiba, HUNGARY</td>
<td>XXX</td>
</tr>
<tr>
<td>Cognitive neurology/neuropsychology 1 (Screen A2)</td>
<td>P1218-P1225</td>
<td>Björn Machner, GERMANY</td>
<td>XXX</td>
</tr>
<tr>
<td>Headache and pain 2 (Screen B1)</td>
<td>P1226-P1232</td>
<td>Dimos Mitsikostas, GREECE</td>
<td>XXX</td>
</tr>
<tr>
<td>Movement disorders 3 (Screen C1)</td>
<td>P1233-P1240</td>
<td>Alexandra Dürr, FRANCE</td>
<td>XXX</td>
</tr>
<tr>
<td>Movement disorders 4 (Screen C2)</td>
<td>P1241-P1249</td>
<td>Carlo Colosimo, ITALY</td>
<td>XXX</td>
</tr>
<tr>
<td>MS and related disorders 3 (Screen C3)</td>
<td>P1250-P1258</td>
<td>Marcin Mycko, POLAND</td>
<td>XXX</td>
</tr>
<tr>
<td>Muscle and neuromuscular junction disease 1 (Screen B2)</td>
<td>P1259-P1265</td>
<td>Richard Orrell, UK</td>
<td>XXX</td>
</tr>
<tr>
<td>Neuroepidemiology (Screen B3)</td>
<td>P1266-P1274</td>
<td>Maurizio Leone, ITALY</td>
<td>XXX</td>
</tr>
<tr>
<td>Neuroimaging 1 (Screen A4)</td>
<td>P1275-P1283</td>
<td>Maria Assunta Rocca, ITALY</td>
<td>XXX</td>
</tr>
<tr>
<td>Sleep disorders 1 (Screen C4)</td>
<td>P1284-P1291</td>
<td>Cistina Panea, ROMANIA</td>
<td>XXX</td>
</tr>
</tbody>
</table>

Will be available throughout the congress on the poster screens and poster stations in front of the exhibition area. You can contact poster presenters via the Interactive Programme Planner IPP.
Poster presenters are requested to be at their poster screen at the beginning of the sessions.

**POSTER SESSION WITH DISCUSSION: SUNDAY, JUNE 21, 2015**

<table>
<thead>
<tr>
<th>TOPIC (SCREEN NR)</th>
<th>POSTER NUMBERS</th>
<th>CHAIRS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autonomic nervous system disorders (Screen C4)</td>
<td>P2101-P2110</td>
<td>David Vodusek, SLOVENIA</td>
<td>XXX</td>
</tr>
<tr>
<td>Cerebrovascular diseases 3 (Screen A1)</td>
<td>P2111-P2119</td>
<td>Adam Kobayashi, POLAND</td>
<td>XXX</td>
</tr>
<tr>
<td>Child and developmental neurology 1 (Screen A2)</td>
<td>P2120-P2125</td>
<td>Daniela Pohl, CANADA</td>
<td>XXX</td>
</tr>
<tr>
<td>Education in neurology (Screen A3)</td>
<td>P2126-P2131</td>
<td>Uta Meyding-Lamade, GERMANY</td>
<td>XXX</td>
</tr>
<tr>
<td>Epilepsy 1 (Screen A3)</td>
<td>P2132-P2139</td>
<td>Torbjorn Tomson, SWEDEN</td>
<td>XXX</td>
</tr>
<tr>
<td>Motor neurone diseases 2 (Screen B2)</td>
<td>P2140-P2146</td>
<td>Krysztof Selmaj, POLAND</td>
<td>XXX</td>
</tr>
<tr>
<td>Movement disorders 5 (Screen B3)</td>
<td>P2147-P2155</td>
<td>Kailash Bhatia, UK</td>
<td>XXX</td>
</tr>
<tr>
<td>MS and related disorders 4 (Screen C1)</td>
<td>P2156-P2164</td>
<td>Maria Pia Amato, ITALY</td>
<td>XXX</td>
</tr>
<tr>
<td>Neurogenetics 2 (Screen A4)</td>
<td>P2165-P2173</td>
<td>Orla Hardiman, IRELAND - TBC</td>
<td>XXX</td>
</tr>
<tr>
<td>Neuroimmunology 1 (Screen C2)</td>
<td>P2174-P2181</td>
<td>Katharina Fink, SWEDEN</td>
<td>XXX</td>
</tr>
<tr>
<td>Neurological manifestations of systemic disease 1 (Screen C3)</td>
<td>P2182-P2189</td>
<td>Ronny Beer, AUSTRIA - TBC</td>
<td>XXX</td>
</tr>
</tbody>
</table>

Will be available throughout the congress on the poster screens and poster stations in front of the exhibition area. You can contact poster presenters via the Interactive Programme Planner IPP.
Poster presenters are requested to be at their poster screen at the beginning of the sessions.

### POSTER SESSION WITH DISCUSSION: SUNDAY, JUNE 21, 2015

<table>
<thead>
<tr>
<th>TOPIC (SCREEN NR)</th>
<th>POSTER NUMBERS</th>
<th>CHAIRS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.30–14.15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebrovascular diseases 4 (Screen A1)</td>
<td>P2201-P2209</td>
<td>XXX</td>
<td></td>
</tr>
<tr>
<td>Clinical neurophysiology 1 (Screen A2)</td>
<td>P2210-P2217</td>
<td>XXX</td>
<td></td>
</tr>
<tr>
<td>Ethics in neurology; History of Neurology; Neurology and Arts (Screen A3)</td>
<td>P2218-P2223</td>
<td>XXX</td>
<td></td>
</tr>
<tr>
<td>Headache and pain 3 (Screen B1)</td>
<td>P2224-P2230</td>
<td>XXX</td>
<td></td>
</tr>
<tr>
<td>Infection and AIDS 2 (Screen B2)</td>
<td>P2231-P2237</td>
<td>XXX</td>
<td></td>
</tr>
<tr>
<td>Movement disorders 6 (Screen B3)</td>
<td>P2238-P2246</td>
<td>XXX</td>
<td></td>
</tr>
<tr>
<td>MS and related disorders 5 (Screen C1)</td>
<td>P2247-P2255</td>
<td>XXX</td>
<td></td>
</tr>
<tr>
<td>Neuroimaging 2 (Screen A4)</td>
<td>P2256-P2264</td>
<td>XXX</td>
<td></td>
</tr>
<tr>
<td>Neurological manifestations of systemic disease 2 (Screen C3)</td>
<td>P2265-P2273</td>
<td>XXX</td>
<td></td>
</tr>
<tr>
<td>Neuro-oncology; neurotoxicology/occupational neurology (Screen C2)</td>
<td>P2274-P2282</td>
<td>XXX</td>
<td></td>
</tr>
<tr>
<td>Spinal cord and root disorders 1 (Screen C4)</td>
<td>P2283-P2292</td>
<td>XXX</td>
<td></td>
</tr>
</tbody>
</table>

Will be available throughout the congress on the poster screens and poster stations in front of the exhibition area. You can contact poster presenters via the Interactive Programme Planner IPP.
Poster presenters are requested to be at their poster screen at the beginning of the sessions.

**POSTER SESSION WITH DISCUSSION: MONDAY, JUNE 22, 2015**

<table>
<thead>
<tr>
<th>TOPIC (SCREEN NR)</th>
<th>POSTER NUMBERS</th>
<th>CHAIRS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebrovascular diseases 5 (Screen A1)</td>
<td>P3101-P3109</td>
<td>Fabienne Perren, SWITZERLAND</td>
<td>XXX</td>
</tr>
<tr>
<td>Child and developmental neurology 2 (Screen B2)</td>
<td>P3110-P3115</td>
<td>Anna Sauerbier, UK</td>
<td>XXX</td>
</tr>
<tr>
<td>Clinical neurophysiology 2 (Screen A2)</td>
<td>P3116-P3123</td>
<td>Jan Kuks, THE NETHERLANDS</td>
<td>XXX</td>
</tr>
<tr>
<td>Cognitive neurology/neuropsychology 2 (Screen A3)</td>
<td>P3124-P3131</td>
<td>Pasquale Calabrese, SWITZERLAND</td>
<td>XXX</td>
</tr>
<tr>
<td>Epilepsy 2 (Screen B1)</td>
<td>P3132-P3139</td>
<td>Erik Tauboll, NORWAY</td>
<td>XXX</td>
</tr>
<tr>
<td>Movement disorders 7 (Screen B3)</td>
<td>P3140-P3148</td>
<td>Alberto Albanese, ITALY</td>
<td>XXX</td>
</tr>
<tr>
<td>MS and related disorders 6 (Screen C1)</td>
<td>P3149-P3157</td>
<td>Ioannis Milonas, GREECE</td>
<td>XXX</td>
</tr>
<tr>
<td>Neurogenetics 3 (Screen A4)</td>
<td>P3158-P3166</td>
<td>Michelangelo Mancuso, ITALY</td>
<td>XXX</td>
</tr>
<tr>
<td>Neuroimmunology 2 (Screen C2)</td>
<td>P3167-P3174</td>
<td>Rana Karabudak, TURKEY - TBC</td>
<td>XXX</td>
</tr>
<tr>
<td>Neuro-ophthalmology/-otology 1 (Screen C3)</td>
<td>P3175-P3183</td>
<td>Detlef Kampf, GERMANY</td>
<td>XXX</td>
</tr>
<tr>
<td>Peripheral nerve disorders 2 (Screen C4)</td>
<td>P3184-P3192</td>
<td>Riadh Gouider, TUNESIA</td>
<td>XXX</td>
</tr>
</tbody>
</table>

Will be available throughout the congress on the poster screens and poster stations in front of the exhibition area. You can contact poster presenters via the Interactive Programme Planner IPP.
Poster presenters are requested to be at their poster screen at the beginning of the sessions.

**POSTER SESSION WITH DISCUSSION: MONDAY, JUNE 22, 2015**

<table>
<thead>
<tr>
<th>TOPIC (SCREEN NR)</th>
<th>POSTER NUMBERS</th>
<th>CHAIRS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.30–14.15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebrovascular diseases 6 (Screen A1)</td>
<td>P3201-P3209</td>
<td>Serefur Öztürk, TURKEY</td>
<td>XXX</td>
</tr>
<tr>
<td>Cognitive neurology/neuropsychology 3 (Screen A3)</td>
<td>P3210-P3217</td>
<td>Theodor Landis, SWITZERLAND</td>
<td>XXX</td>
</tr>
<tr>
<td>Critical care (Screen A2)</td>
<td>P3218-P3225</td>
<td>Manfred Kaps, GERMANY</td>
<td>XXX</td>
</tr>
<tr>
<td>Epilepsy 3 (Screen B1)</td>
<td>P3226-P3233</td>
<td>Geert Mayer, GERMANY</td>
<td>XXX</td>
</tr>
<tr>
<td>Movement disorders B (Screen B3)</td>
<td>P3234-P3242</td>
<td>Andrea Kühn, GERMANY - TBC</td>
<td>XXX</td>
</tr>
<tr>
<td>MS and related disorders 7 (Screen C1)</td>
<td>P3243-P3251</td>
<td>Wolfgang Köhler, GERMANY</td>
<td>XXX</td>
</tr>
<tr>
<td>Muscle and neuromuscular junction disease 2 (Screen B2)</td>
<td>P3252-P3259</td>
<td>Benedikt Schoser, GERMANY</td>
<td>XXX</td>
</tr>
<tr>
<td>Neurorehabilitation, neuro-traumatology (Screen A4)</td>
<td>P3260-P3270</td>
<td>Volker Dietz, SWITZERLAND</td>
<td>XXX</td>
</tr>
<tr>
<td>Peripheral nerve disorders 3 (Screen C4)</td>
<td>P3271-P3278</td>
<td>Claudia Sommer, GERMANY</td>
<td>XXX</td>
</tr>
<tr>
<td>Spinal cord and root disorders 2 (Screen C2)</td>
<td>P3279-P3288</td>
<td>Ellen Merete Hagen, NORWAY</td>
<td>XXX</td>
</tr>
</tbody>
</table>

Will be available throughout the congress on the poster screens and poster stations in front of the exhibition area. You can contact poster presenters via the Interactive Programme Planner IPP.
Poster presenters are requested to be at their poster screen at the beginning of the sessions.

**POSTER SESSION WITH DISCUSSION: TUESDAY, JUNE 23, 2015**

<table>
<thead>
<tr>
<th>TOPIC (SCREEN NR)</th>
<th>POSTER NUMBERS</th>
<th>CHAIRS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>10.45–11.30</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ageing and dementia 3 (Screen A1)</td>
<td>P4101–P4108</td>
<td>Sokratis Papageorgiou, GREECE</td>
<td>XXX</td>
</tr>
<tr>
<td>Clinical neurophysiology 3 (Screen A2)</td>
<td>P4109–P4115</td>
<td>Werner Mess, THE NETHERLANDS</td>
<td>XXX</td>
</tr>
<tr>
<td>Epilepsy 4 (Screen A3)</td>
<td>P4116–P4123</td>
<td>Jera Kruja, ALBANIA</td>
<td>XXX</td>
</tr>
<tr>
<td>Motor neurone diseases 3 (Screen B1)</td>
<td>P4124–P4130</td>
<td>Jean-Michel Vailat, FRANCE</td>
<td>XXX</td>
</tr>
<tr>
<td>Movement disorders 9 (Screen B2)</td>
<td>P4131–P4138</td>
<td>Mark Edwards, UK</td>
<td>XXX</td>
</tr>
<tr>
<td>MS and related disorders 8 (Screen C1)</td>
<td>P4139–P4146</td>
<td>Celia Oreja-Guevara, SPAIN</td>
<td>XXX</td>
</tr>
<tr>
<td>MS and related disorders 9 (Screen C2)</td>
<td>P4147–P4155</td>
<td>Valmantas Budrys, LITHUANIA - TBC</td>
<td>XXX</td>
</tr>
<tr>
<td>Neurogenetics 4 (Screen A4)</td>
<td>P4156–P4163</td>
<td>Antonio Federico, ITALY</td>
<td>XXX</td>
</tr>
<tr>
<td>Neuroimaging 3 (Screen B3)</td>
<td>P4164–P4171</td>
<td>Christian Enzinger, AUSTRIA</td>
<td>XXX</td>
</tr>
<tr>
<td>Neuro-ophthalmology/neuro-otology 2 (Screen C3)</td>
<td>P4172–P4179</td>
<td>Adolfo Bronstein, UK</td>
<td>XXX</td>
</tr>
<tr>
<td>Sleep disorders 2 (Screen C4)</td>
<td>P4180–P4186</td>
<td>Poul Jennum, DENMARK</td>
<td>XXX</td>
</tr>
<tr>
<td><strong>11.45–12.30</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Movement disorders 10 (Screen B2)</td>
<td>F4201–F4208</td>
<td>Jozef Opara, POLAND</td>
<td>XXX</td>
</tr>
<tr>
<td>MS and related disorders 10 (Screen C1)</td>
<td>F4209–F4217</td>
<td>Ludwig Kappos, SWITZERLAND</td>
<td>XXX</td>
</tr>
<tr>
<td>MS and related disorders 11 (Screen C2)</td>
<td>F4218–F4225</td>
<td>Achim Gass, GERMANY - TBC</td>
<td>XXX</td>
</tr>
</tbody>
</table>

Will be available throughout the congress on the poster screens and poster stations in front of the exhibition area. You can contact poster presenters via the Interactive Programme Planner IPP.
Poster presenters are requested to be at their poster screen at the beginning of the sessions.

**FLASH POSTER SESSION: SATURDAY, JUNE 20, 2015**

<table>
<thead>
<tr>
<th>TOPIC (SCREEN NR)</th>
<th>POSTER NUMBERS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.30–13.15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Child neurology; Education in neurology; Neuroethics; History of neurology; Neurology and arts (Screen C1)</td>
<td>F1001-F1019</td>
<td>XXX</td>
</tr>
<tr>
<td>Cognitive neurology/ neuropsychology (Screen A7)</td>
<td>F1020-F1034</td>
<td>XXX</td>
</tr>
<tr>
<td>Epilepsy 1 (Screen A9)</td>
<td>F1035-F1049</td>
<td>XXX</td>
</tr>
<tr>
<td>Infection and AIDS (Screen B5)</td>
<td>F1050-F1067</td>
<td>XXX</td>
</tr>
<tr>
<td>Movement disorders 1 (Screen B9)</td>
<td>F1068-F1082</td>
<td>XXX</td>
</tr>
<tr>
<td>Neuroimmunology 1 (Screen A5)</td>
<td>F1083-F1094</td>
<td>XXX</td>
</tr>
<tr>
<td>Neuro-oncology (Screen C7)</td>
<td>F1095-F1111</td>
<td>XXX</td>
</tr>
<tr>
<td>13.30–14.15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical neurophysiology (Screen C7)</td>
<td>F1112-F1122</td>
<td>XXX</td>
</tr>
<tr>
<td>Epilepsy 2 (Screen B9)</td>
<td>F1123-F1137</td>
<td>XXX</td>
</tr>
<tr>
<td>Neurogenetics (Screen A7)</td>
<td>F1138-F1148</td>
<td>XXX</td>
</tr>
<tr>
<td>Neurological manifestations of systemic disease (Screen A9)</td>
<td>F1149-F1163</td>
<td>XXX</td>
</tr>
<tr>
<td>Neuro-ophthalmology/-otology (Screen B5)</td>
<td>F1164-F1179</td>
<td>XXX</td>
</tr>
<tr>
<td>Neurotraumatology; Critical care (Screen A5)</td>
<td>F1180-F1195</td>
<td>XXX</td>
</tr>
<tr>
<td>Sleep disorders (Screen C5)</td>
<td>F1196-F1205</td>
<td>XXX</td>
</tr>
</tbody>
</table>

Will be available throughout the congress on the poster screens and poster stations in front of the exhibition area. You can contact poster presenters via the Interactive Programme Planner IPP.
Poster presenters are requested to be at their poster screen at the beginning of the sessions.

**FLASH POSTER SESSION: SUNDAY, JUNE 21, 2015**

<table>
<thead>
<tr>
<th>TOPIC (SCREEN NR)</th>
<th>POSTER NUMBERS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12.30–13.15</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ageing and dementia 1 (Screen A7)</td>
<td>F2001-F2018</td>
<td>XXX</td>
</tr>
<tr>
<td>Cerebrovascular diseases 1 (Screen C5)</td>
<td>F2019-F2035</td>
<td>XXX</td>
</tr>
<tr>
<td>Cerebrovascular diseases 2 (Screen C7)</td>
<td>F2036-F2050</td>
<td>XXX</td>
</tr>
<tr>
<td>Movement disorders 2 (Screen A5)</td>
<td>F2051-F2065</td>
<td>XXX</td>
</tr>
<tr>
<td>MS and related disorders 1 (Screen B5)</td>
<td>F2066-F2084</td>
<td>XXX</td>
</tr>
<tr>
<td>Muscle and neuromuscular junction disease 1 (Screen A9)</td>
<td>F2085-F2096</td>
<td>XXX</td>
</tr>
<tr>
<td>Neuroimaging 1 (Screen B9)</td>
<td>F2097-F2108</td>
<td>XXX</td>
</tr>
<tr>
<td><strong>13.30–14.15</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebrovascular diseases 3 (Screen C5)</td>
<td>F1109-F1123</td>
<td>XXX</td>
</tr>
<tr>
<td>Headache and pain 1 (Screen C7)</td>
<td>F1124-F1139</td>
<td>XXX</td>
</tr>
<tr>
<td>Movement disorders 3 (Screen A7)</td>
<td>F1140-F1153</td>
<td>XXX</td>
</tr>
<tr>
<td>MS and related disorders 2 (Screen B5)</td>
<td>F1154-F1173</td>
<td>XXX</td>
</tr>
<tr>
<td>Neurorehabilitation (Screen A9)</td>
<td>F1174-F1193</td>
<td>XXX</td>
</tr>
<tr>
<td>Peripheral nerve disorders 1 (Screen B9)</td>
<td>F1194-F1206</td>
<td>XXX</td>
</tr>
</tbody>
</table>

Will be available throughout the congress on the poster screens and poster stations in front of the exhibition area. You can contact poster presenters via the Interactive Programme Planner IPP.
Poster presenters are requested to be at their poster screen at the beginning of the sessions.

**FLASH POSTER SESSION: MONDAY, JUNE 22, 2015**

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>POSTER NUMBERS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12.30–13.15</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ageing and dementia 2 (Screen A5)</td>
<td>F3001-F3017</td>
<td>XXX</td>
</tr>
<tr>
<td>Cerebrovascular diseases 4 (Screen C5)</td>
<td>F3018-F3032</td>
<td>XXX</td>
</tr>
<tr>
<td>Headache and pain 2 (Screen A9)</td>
<td>F3033-F3048</td>
<td>XXX</td>
</tr>
<tr>
<td>MS and related disorders 3 (Screen A9)</td>
<td>F3049-F3056</td>
<td>XXX</td>
</tr>
<tr>
<td>Muscle and neuromuscular junction disease 2 (Screen B5)</td>
<td>F3067-F3078</td>
<td>XXX</td>
</tr>
<tr>
<td>Neuroepidemiology; neurotoxicology; Autonomic nervous system disorders (Screen C7)</td>
<td>F3079-F3092</td>
<td>XXX</td>
</tr>
<tr>
<td><strong>13.30–14.15</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebrovascular diseases 5 (Screen B5)</td>
<td>F3093-F3108</td>
<td>XXX</td>
</tr>
<tr>
<td>Motor neurone diseases (Screen A5)</td>
<td>F3109-F3120</td>
<td>XXX</td>
</tr>
<tr>
<td>Movement disorders 4 (Screen A9)</td>
<td>F3121-F3135</td>
<td>XXX</td>
</tr>
<tr>
<td>MS and related (Screen B9)</td>
<td>F3136-F3153</td>
<td>XXX</td>
</tr>
<tr>
<td>Neuroimaging 2 (Screen C5)</td>
<td>F3154-F3165</td>
<td>XXX</td>
</tr>
</tbody>
</table>

Will be available throughout the congress on the poster screens and poster stations in front of the exhibition area. You can contact poster presenters via the Interactive Programme Planner IPP.
Poster presenters are requested to be at their poster screen at the beginning of the sessions.

**FLASH POSTER SESSION: TUESDAY, JUNE 23, 2015**

<table>
<thead>
<tr>
<th>TIME</th>
<th>TOPIC</th>
<th>SCREEN</th>
<th>POSTER NUMBERS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>12.30–13.15</strong></td>
<td>Cerebrovascular diseases 6 (Screen A5)</td>
<td></td>
<td>F4001-F4015</td>
<td>XXX</td>
</tr>
<tr>
<td></td>
<td>Cerebrovascular diseases 7 (Screen A7)</td>
<td></td>
<td>F4016-F4030</td>
<td>XXX</td>
</tr>
<tr>
<td></td>
<td>Neuroimmunology 2 (Screen B9)</td>
<td></td>
<td>F4031-F4042</td>
<td>XXX</td>
</tr>
<tr>
<td></td>
<td>Peripheral nerve disorders 2 (Screen B5)</td>
<td></td>
<td>F4043-F4055</td>
<td>XXX</td>
</tr>
<tr>
<td></td>
<td>Spinal cord and root disorders (Screen C5)</td>
<td></td>
<td>F4056-F4066</td>
<td>XXX</td>
</tr>
<tr>
<td><strong>13.30–14.15</strong></td>
<td>Cerebrovascular diseases 8 (Screen A5)</td>
<td></td>
<td>F4067-F4082</td>
<td>XXX</td>
</tr>
<tr>
<td></td>
<td>Cerebrovascular diseases 9 (Screen A7)</td>
<td></td>
<td>F4083-F4097</td>
<td>XXX</td>
</tr>
<tr>
<td></td>
<td>Movement disorders 5 (Screen C5)</td>
<td></td>
<td>F4098-F4109</td>
<td>XXX</td>
</tr>
<tr>
<td></td>
<td>MS and related disorders 5 (Screen B9)</td>
<td></td>
<td>F4110-F4127</td>
<td>XXX</td>
</tr>
</tbody>
</table>

Will be available throughout the congress on the poster screens and poster stations in front of the exhibition area. You can contact poster presenters via the Interactive Programme Planner IPP.
OPENING CEREMONY

Saturday, June 20, 2015.
During the Opening Ceremony the EAN will welcome all participants to this unique congress which will mark a milestone in European Neurology.

PROGRAMME
Chairpersons: Paul Boon, Günther Deuschl, Wolfgang Oertel

"Welcoming words"
Wolfgang Oertel, Marburg, Germany
Local Chairperson

"About the WFN"
Raad Shakir, London, UK
President of the WFN

"The first steps of a new Society"
Günther Deuschl, Kiel Germany
EAN President

"Awards to EAN Honorary members"

"What can musicians teach neurologists?"
Eckart Altenmüller, Hannover, Germany

followed by a musical performance by the Comedian Harmonists

All participants and exhibitors are invited to the Opening Ceremony and Welcome Reception.
Please wear your badge.
**CHARITÉ HOSPITAL – 20.00 H**

**Sunday, June 21, 2015.**

“From the Venetian Gondola to the Gardens of Granada”
– A musical Expedition –
Vivaldi, Stravinsky, Brahms, de Falla

This concert is organised by Prof. Dr. Klaus V. Toyka and belongs to the concert series “Music at the Neurology”. It is organised on the occasion of the 1st Congress of the EAN.

Tickets are EUR 12 per person.
Venue:
Lecture Hall - Department of Dermatology
Charité Hospital, Humboldt University - Entrance: Luisenstrasse 2

**REGISTRATION:**
In order to purchase tickets, please proceed to the secretariat.

**NETWORKING RECEPTION AT CHARLOTTENBURG PALACE**

**Monday, June 22, 2015, starting at 20.15h.**

The Networking Event will be held at the Orangerie in the famous Schloss Charlottenburg.
Charlottenburg Palace is the largest palace in Berlin, and the only surviving royal residence in the city dating back to the time of the Hohenzollern family.

The palace was built at the end of the 17th century and was greatly expanded during the 18th century. It is famous for its baroque and rococo style decoration. A large formal garden surrounded by woodland was added behind the palace, including a belvedere, a mausoleum, a theatre and a pavilion. During the Second World War, the palace was badly damaged but has since been reconstructed.
Join this exciting event with a lot of surprises and a delicious culinary treat and use the opportunity to network with your friends and colleagues in a unique and historic surrounding.

Tickets are EUR 95,- per person and EUR 60,- for young neurologists and participants from middle/low income countries as well as retired persons. Food and drinks included.

REGISTRATION:
The number of tickets is limited and will be distributed on ‘first-come first-served’ basis at the registration desk.

HOW TO GET THERE:
Distance from CityCube: 4.5 km; Kurfürstendamm: 2.8 km; Alexanderplatz: 10 km; Berlin Hbf: 7 km

- S-Bahn up to Westend; 3 stops by bus M45 up to Charlottenburg Palace (direction Zoologischer Garten)
- Underground (U-Bahn) line 7 up to Richard-Wagner-Platz, then bus M45 up to Charlottenburg Palace, or approx. 15 minutes walking distance (direction Johannesstift)
- Bus M45 from Zoologischer Garten (direction Johannesstift), or Bus 109 (direction Tegel airport) up to Charlottenburg Palace
FIRST EUROPEAN CONGRESS on Hereditary ATTR amyloidosis

IMPROVING CLINICAL MANAGEMENT

November 2 and 3, 2015

Co-organizers David Adams (Paris, France)
and Teresa Coelho (Porto, Portugal)

MAIN TOPICS:
- Epidemiology of TTR-FAP in Europe
- Genotypes and phenotypes
- Diagnosis and staging
- New tools for diagnosis
- Disease modifying therapies
- Clinical trials
- Genetic counseling and reproduction
- Novelties in symptomatic therapies

Institut Pasteur - 25-28 rue du Docteur Roux - 75015 Paris - France

www.ec-attr.com
## Timetable

### Saturday, June 20, 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:30</td>
<td>Sy1 Management of spontaneous intracerebral haemorrhage</td>
</tr>
<tr>
<td>08:30-10:30</td>
<td>Sy2 Epilepsy</td>
</tr>
<tr>
<td>08:30-10:30</td>
<td>Sy3 Modern molecular genetics in clinical myology and future</td>
</tr>
<tr>
<td>10:30-12:30</td>
<td>IS1 Update on vestibular disorders</td>
</tr>
<tr>
<td>10:30-12:30</td>
<td>FW1 Innovative approach to MS therapy - antigen induced immune tolerance</td>
</tr>
<tr>
<td>10:30-12:30</td>
<td>FW2 Migraine biomarkers: facts, fiction &amp; future</td>
</tr>
<tr>
<td>10:30-12:30</td>
<td>FW3 Cognitive deterioration after stroke - detection, prevention and treatment</td>
</tr>
<tr>
<td>10:30-12:30</td>
<td>FW4 Metals and movement disorders</td>
</tr>
<tr>
<td>10:30-12:30</td>
<td>FW5 Human spatial orientation</td>
</tr>
<tr>
<td>10:30-12:30</td>
<td>FW6 Neurogenetics: Who, when and which test?</td>
</tr>
<tr>
<td>10:30-12:30</td>
<td>FW7 Neurophysiological evaluation of autonomic nervous system dysfunction</td>
</tr>
<tr>
<td>10:30-12:30</td>
<td>FW8 Gut and brain</td>
</tr>
<tr>
<td>11:00-12:30</td>
<td>HOC1 Biogen Satellite Symposium: A multiple sclerosis patient journey: what drives decisions?</td>
</tr>
<tr>
<td>11:00-12:30</td>
<td>SaS UCB Epilepsy Satellite Symposium: The Hippocratic Oath &quot;Do no harm&quot; - Considerations for the long-term treatment of chronic neurological diseases</td>
</tr>
<tr>
<td>11:00-12:30</td>
<td>SaS Dr. Willmar Schwabe Satellite Symposium: Expectations management for neurocognitive disorders patients</td>
</tr>
<tr>
<td>12:30-13:15</td>
<td>Poster Session 1</td>
</tr>
<tr>
<td>13:00-14:30</td>
<td>TC1 Basic management issues of stroke Level 1</td>
</tr>
<tr>
<td>13:00-14:30</td>
<td>TC2 Current treatments in neurology I Level 1</td>
</tr>
<tr>
<td>13:00-14:30</td>
<td>TC3 New advances in the treatment of immune mediated neuropathies Level 3</td>
</tr>
<tr>
<td>13:00-14:30</td>
<td>TC4 Diagnosis and differential diagnosis of ALS Level 2</td>
</tr>
<tr>
<td>13:00-14:30</td>
<td>TC5 Epilepsy - basic approach to a seizing patient Level 1</td>
</tr>
<tr>
<td>13:00-14:30</td>
<td>TC6 The aging brain Level 1</td>
</tr>
<tr>
<td>13:00-14:30</td>
<td>OS Peripheral nerve disorders 1</td>
</tr>
<tr>
<td>13:00-14:30</td>
<td>OS Neurogenetics</td>
</tr>
<tr>
<td>13:00-14:30</td>
<td>OS Neurotraumatology and rehabilitation</td>
</tr>
<tr>
<td>15:45-16:15</td>
<td>Coffee break</td>
</tr>
<tr>
<td>16:00-17:30</td>
<td>OS Movement disorders 2</td>
</tr>
<tr>
<td>16:00-17:30</td>
<td>OS Multiple sclerosis and related disorders 2</td>
</tr>
<tr>
<td>16:00-17:30</td>
<td>OS Neuro-ophthalmology/ -otology</td>
</tr>
<tr>
<td>16:00-17:30</td>
<td>OS Clinical neurophysiology</td>
</tr>
<tr>
<td>16:00-17:30</td>
<td>OS Sleep disorders</td>
</tr>
<tr>
<td>18:30 – 19:30</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>19:30 – 21:00</td>
<td>Welcome Reception</td>
</tr>
</tbody>
</table>
## FINAL PROGRAMME

**BERLIN, GERMANY, 20 – 23 JUNE, 2015**

### FINAL PROGRAMME

**BERLIN, GERMANY, 20 – 23 JUNE, 2015**

### HALL 2.2

- **HALL 2.2**
  - **HALL A8**
    - **HALL A6**
      - **HALL A5**
        - **HALL A4**
          - **HALL A3**
            - **HALL A2**
              - **HALL A1**
                - **HALL M2+3**
                  - **HALL M1**
                    - **EXHIBITION/POSTER**

### TIMETABLE

**SUNDAY, JUNE 21, 2015**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-11:00</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>
| 11:00-12:30| Novartis Satellite Symposium
  - **SaS**
  - **07:00-08:30**
  - **Novartis Satellite Symposium**
  - **MS in the real world**
| 12:30-13:15| Lunch Break              |
| 13:00-14:30| Coffee break             |
| 14:45-18:15| Multiple sclerosis Level 3
  - **OS**
  - **14:45-16:15**
  - **Cerebrovascular diseases 1**
  - **16:15-16:45**
  - **Coffee break**
  - **16:45-18:15**
  - **Peripheral nerve disorders 2**
| 18:30-20.00| Teva Satellite Symposium
  - **SaS**
  - **18:30-20.00**
  - **New challenges in multiple sclerosis**
| 18:30-20.00| Eisai Satellite Symposium
  - **SaS**
  - **Generalised seizures: challenges and solutions**
| 18:30-20.00| Bial Satellite Symposium
  - **SaS**
  - **Review of COMT inhibitor therapy in Parkinson's disease**
| 18:30-20.00| Takeda Satellite Symposium
  - **SaS**
  - **Post-stroke cognitive impairment: challenges and new treatment strategies**

**2015**

---

**XLIII**
## TIMETABLE

### MONDAY, JUNE 22, 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:30</td>
<td>Early/preclinical Alzheimer's disease</td>
</tr>
<tr>
<td>08:30-10:30</td>
<td>Expanding fields in neurology</td>
</tr>
<tr>
<td>08:30-10:30</td>
<td>Present and future treatment in movement disorders</td>
</tr>
<tr>
<td>07.00-08.30</td>
<td>Neurophysiology III - advanced</td>
</tr>
<tr>
<td>10.00-17.00</td>
<td>Exhibition/Poster</td>
</tr>
<tr>
<td>10:30-11:00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>Movement and gait disorders</td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>Non-coding RNA in multiple sclerosis - from pathogenesis to therapy</td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>Novel approaches for the rehabilitation of movement disorders after stroke</td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>Autoimmune myasthenia gravis</td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>Non-pharmacological issues in dementia</td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>Infections of the nervous system: The impact of a changing environment on epidemiology, course of disease and change in pathogenesis</td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>Adult-onset leukodystrophies</td>
</tr>
<tr>
<td>11.00-12.30</td>
<td>Antibodies in neuropathy</td>
</tr>
<tr>
<td>13.00-14.30</td>
<td>European Basal Ganglia Club</td>
</tr>
<tr>
<td>13.00-14.30</td>
<td>Neuro-otology</td>
</tr>
<tr>
<td>13.00-14.30</td>
<td>Genzyme Satellite Symposium From MOA to clinical treatment decisions. Is there a new way of thinking in MS?</td>
</tr>
<tr>
<td>13.00-14.30</td>
<td>Zambon Satellite Symposium Changing the treatment paradigm in mid- to late-stage PD: Extending stability in Parkinson's disease</td>
</tr>
<tr>
<td>13.00-14.30</td>
<td>Eisai Satellite Symposium Optimizing epilepsy therapy – searching for the evidence, looking beyond the data</td>
</tr>
<tr>
<td>13.00-14.30</td>
<td>Pfizer Satellite Symposium A rare disease that demands our collaborative approach - TTR-familial amyloid polyneuropathy (TTR-FAP)</td>
</tr>
<tr>
<td>12.30-13.15</td>
<td>Poster Session 3</td>
</tr>
<tr>
<td>14.45-18.15</td>
<td>Parkinson's disease treatment: infusion therapies and DBS Level 1</td>
</tr>
<tr>
<td>14.45-18.15</td>
<td>Therapeutic strategies in multiple sclerosis Level 1-2</td>
</tr>
<tr>
<td>14.45-18.15</td>
<td>Epilepsy - management of the refractory patient Level 3</td>
</tr>
<tr>
<td>14.45-18.15</td>
<td>Facial pain: diagnosis and management Level 2</td>
</tr>
<tr>
<td>14.45-18.15</td>
<td>Interventions in neurocritical care Level 2</td>
</tr>
<tr>
<td>14.45-18.15</td>
<td>Impact and management of sleep disorders in neurology Level 1</td>
</tr>
<tr>
<td>14.45-18.15</td>
<td>Tournament (basic)</td>
</tr>
<tr>
<td>14.45-16.45</td>
<td>Cerebrovascular diseases 2</td>
</tr>
<tr>
<td>14.45-16.45</td>
<td>Cognitive neurology</td>
</tr>
<tr>
<td>14.45-16.45</td>
<td>Neuroimaging</td>
</tr>
<tr>
<td>16.45-18.15</td>
<td>Late breaking News</td>
</tr>
<tr>
<td>17.00-20.00</td>
<td>Back to basics in neuroimmunology: what every neurologist needs to know and why!</td>
</tr>
<tr>
<td>Session</td>
<td>Time</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>Sy7</td>
<td>08:00-10:00</td>
</tr>
<tr>
<td>Sy8</td>
<td>08:00-10:00</td>
</tr>
<tr>
<td>Exhibition</td>
<td>09:00-13:30</td>
</tr>
<tr>
<td>Exhibition</td>
<td>10:00-10:30</td>
</tr>
<tr>
<td>EAYNT Session</td>
<td>09:00-13:30</td>
</tr>
<tr>
<td>EAN &amp; PAUNS</td>
<td>09:00-13:30</td>
</tr>
<tr>
<td>Coffee break</td>
<td>10:00-10:30</td>
</tr>
<tr>
<td>Lunch Break</td>
<td>12:00-13:00</td>
</tr>
<tr>
<td>Poster Session 4</td>
<td>13.00-16.30</td>
</tr>
<tr>
<td>Clinical and therapeutical approach to muscle disorders</td>
<td>13.00-16.30</td>
</tr>
<tr>
<td>The neurological bedside examination</td>
<td>13.00-16.30</td>
</tr>
<tr>
<td>Assessment of neuropathic pain in clinical practice</td>
<td>13.00-16.30</td>
</tr>
<tr>
<td>Current treatment in neurology II</td>
<td>13.00-16.30</td>
</tr>
<tr>
<td>Atypical Alzheimer’s disease</td>
<td>13.00-16.30</td>
</tr>
<tr>
<td>The spectrum of neuro-oncology</td>
<td>13.00-16.30</td>
</tr>
</tbody>
</table>

**TIMETABLE**

**TUESDAY, JUNE 23, 2015**

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focused Workshop</td>
<td>08:00-10:00</td>
<td>Hall A8</td>
<td>Focused Workshop</td>
<td></td>
</tr>
<tr>
<td>Interactive Session</td>
<td>08:00-10:00</td>
<td>Hall A8</td>
<td>Interactive Session</td>
<td></td>
</tr>
<tr>
<td>Oral Session</td>
<td>08:00-10:00</td>
<td>Hall A8</td>
<td>Oral Session</td>
<td></td>
</tr>
<tr>
<td>Satellite Symposium</td>
<td>08:00-10:00</td>
<td>Hall A8</td>
<td>Satellite Symposium</td>
<td></td>
</tr>
<tr>
<td>Teaching Course</td>
<td>08:00-10:00</td>
<td>Hall A8</td>
<td>Teaching Course</td>
<td></td>
</tr>
<tr>
<td>Tournament</td>
<td>08:00-10:00</td>
<td>Hall A8</td>
<td>Tournament</td>
<td></td>
</tr>
<tr>
<td>Coffee break</td>
<td>10:45-11:30</td>
<td>Hall A8</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>Coffee break</td>
<td>11:45-12:30</td>
<td>Hall A8</td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>

**KEY:**
- Focused Workshop (FW)
- Interactive Session (IS)
- Oral Session (OS)
- Satellite Symposium (SaS)
- Teaching Course (TC)
- Tournament (T)
- Hands-on-course (HOC)
- Networking Events (NE)
FREE 30 DAY ONLINE TRIAL
HIGH IMPACT, CUTTING EDGE RESEARCH FROM BMJ JOURNALS. bmj.com

JOURNAL OF NEUROINTERVENTIONAL SURGERY
jniss.bmj.com
FREE ONLINE TRIAL:
response.jniss@bmj.com
A leading peer review journal for scientific research and literature pertaining to the field of neurointerventional surgery.

JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY
jnnp.bmj.com
FREE ONLINE TRIAL:
response.jnnp@bmj.com
Publishing the most groundbreaking and cutting-edge research from around the world, encompassing the entire genre of neurological sciences.

PRACTICAL NEUROLOGY
pn.bmj.com
FREE ONLINE TRIAL:
response.pn@bmj.com
A journal for everyone who sees neurological patients and who wants to keep up to date, and safe, in managing them.

BMJ's suite of world-class neurology journals publishes high-impact, cutting-edge research from around the world. To find out more, and to chat with some of our team members, visit us at booth no. E07!
HIGH-IMPACT, CUTTING-EDGE RESEARCH FROM BMJ

BMJ's suite of world-class neurology journals publishes high-impact, cutting-edge research from around the world.

To find out more, and to chat with some of our team members, visit us at booth no. E07!

**JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY**
jnnp.bmj.com
FREE ONLINE TRIAL: response.jnnp@bmj.com
Publishing the most ground-breaking and cutting-edge research from around the world, encompassing the entire genre of neurological sciences.

**PRACTICAL NEUROLOGY**
pn.bmj.com
FREE ONLINE TRIAL: response.pn@bmj.com
A journal for everyone who sees neurological patients and who wants to keep up to date, and safe, in managing them.

**JOURNAL OF NEUROINTERVENTIONAL SURGERY**
jnis.bmj.com
FREE ONLINE TRIAL: response.jnis@bmj.com
A leading peer review journal for scientific research and literature pertaining to the field of neurointerventional surgery.

journals.bmj.com
XXII World Congress of Neurology
Santiago - Chile 2015
Changing Neurology Worldwide
Santiago, Chile, October 31 - November 5, 2015

REGISTER EARLY AND SAVE
EARLY BIRD REGISTRATION DEADLINE: JULY 6 2015

WCN 2015

www.wcn-neurology.com
Consortium of Multiple Sclerosis Centers

JOIN THE MS TEAM

Celebrating 30 years of MS Care

www.mscare.org
Publish your next piece of research in

**Alzheimer's Research and Therapy**

Editors-in-Chief: Douglas R Galasko, Todd E Golde, Philip Scheltens

The major forum for translational research in Alzheimer's dementia and other neurodegenerative diseases.

- Rapid peer review and immediate publication on acceptance
- Unique focus on translational research
- Open access content: freely available online
- Prestigious and international Editorial Board

For more information please contact editorial@alzres.com

alzres.com  alz.co.uk  biomedcentral.com
SYMPOSIUM 1
EAN-ESO SYMPOSIUM: SPONTANEOUS INTRACEREBRAL HAEMORRHAGE

Chairpersons:
Valeria Caso, PERUGIA, ITALY
Charlotte Cordonnier, LILLE, FRANCE

Causes and clinical course of spontaneous intracerebral haemorrhages
Valeria Caso, PERUGIA, ITALY

Work-up of intra-cerebral haemorrhages
Rustam Al-Shahi Salman, EDINBURGH, UK

Microbleeds, small vessel disease and intracerebral haemorrhages
Charlotte Cordonnier, LILLE, FRANCE

Treatment and current perspectives
Daniel Hanley, BALTIMORE, USA
SYMPOSIUM 2
EPILEPSY AND THE INJURED BRAIN: CAUSES AND CONSEQUENCES

Chairpersons:
Matthew Walker, LONDON, UK
Annamaria Vezzani, MILAN, ITALY - TBC

The role of inflammation – animal and clinical data
Annamaria Vezzani, MILAN, ITALY

Managing seizures and seizure risk in the acutely injured
Martin Holtkamp, BERLIN, GERMANY

Predicting epilepsy risk after acute brain insults
Torbjörn Tomson, STOCKHOLM, SWEDEN

Preventing epilepsy following an acute brain insult - fact or fiction
Matthew Walker, LONDON, UK
SYMPOSIUM 3
MODERN MOLECULAR GENETICS IN CLINICAL MYOLOGY

Chairpersons:
Zohar Argov, JERUSALEM, ISRAEL
Stephan Zierz, HALLE, GERMANY - TBC

Overview in epidemiology and classification in myology
Zohar Argov, JERUSALEM, ISRAEL

Myotonic dystrophies and upcoming therapies
Benedikt Schoser, MUNICH, GERMANY

Dystrophinopathies: from steroids to molecular therapy
Corrado Angelini, PADOVA, ITALY

The value of next generation sequencing in diagnosing neuromuscular disorders
Volker Straub, NEWCASTLE, UK
FOCUSED WORKSHOP 1
INNOVATIVE APPROACH TO MS THERAPY – ANTIGEN-INDUCED IMMUNE TOLERANCE

Chairperson:
Krysztof Selmaj, LODZ, POLAND

Antigen-induced tolerance: Highly selective intervention in MS treatment
Lawrence Steinman, STANFORD, USA

MS treatment with autologous myelin peptide-coupled cells
Roland Martin, ZURICH, SWITZERLAND

MS Treatment with myelin skin patients
Krysztof Selmaj, LODZ, POLAND
Migraine is diagnosed on the basis of clinical criteria defined by the International Classification of Headache Disorders. It is common clinical experience, however, that migraine patients have varying expressions of symptoms and varying responses to therapies. Biomarkers would thus be uttermost importance to identify subgroups of migraineurs with common underlying disease mechanisms. In recent years, our knowledge on genetics, neuroimaging features and neurophysiological profiles of migraine patients has vastly expanded. It seems timely to examine what the correlations are between the clinical migraine phenotype and these biomarkers, and if and how they relate to each other. The workshop will allow synoptically reviewing the various biomarkers and providing elements of answers to these questions.
This workshop reports on recent advances in the area of post-stroke cognitive deterioration including its most frequent manifestations in clinical practice. Varying definitions used result in different prevalence rates and genetic as well as imaging markers allow us to improve the description of these disorders. Previously, cognitive deterioration following stroke was largely seen as inevitable but nowadays therapeutic options are discussed. Therefore, also ongoing clinical trials are reported as well as the results of some multi-interventional lifestyle adaptation trials.
FOCUSED WORKSHOP 4
METALS AND MOVEMENT DISORDERS

Chairperson:
Kailash Bhatia, LONDON, UK

Iron - NBIAs
Kailash Bhatia, LONDON, UK

Manganese
Vincenzo Bonifati, ROTTERDAM, THE NETHERLANDS

Copper - Wilson’s disease
Anna Członkowska, WARSAW, POLAND
Human spatial orientation: Theoretical aspects: how can we stand and move in the world around us?
Alain Berthoz, PARIS, FRANCE

Human spatial orientation: Neuro-oto- and ophthalmological aspects
Adolfo Bronstein, LONDON, UK

Human spatial orientation: Clinical aspects
Thomas Brandt, MUNICH, GERMANY

Our ability to orient ourselves in space appears trivial. If, however, we lack this awareness, we are disoriented – not in time or in person but in place. Spatial orientation defines our body orientation relative to the surrounding space – at rest and during locomotion and navigation. Evolutionarily speaking, human survival on planet Earth critically depends on maintaining spatial orientation. Vestibular and visual cues give the coordinates of the brain’s continuous representation of the individual within the 3-D environment, making orientation and navigation in space at all possible. The present workshop will elucidate the neurophysiology of spatial orientation and its disorders.
FOCUSED WORKSHOP 6
NEUROGENETICS: WHO, WHEN AND WHICH TEST?

Chairperson:
Alexandra Dürr, PRAIS, FRANCE

Genetics in Parkinson’s disease
Christine Klein, LUBECK, GERMANY

Genetics of motorneuron disease
Richard W. Orrell, LONDON, UK

Genetics of cerebellar ataxias
Alexandra Dürr, PARIS, FRANCE

1. Understand the genetic heterogeneity of three groups of diseases, Parkinson Disease, dementias and cerebellar ataxias and recognize phenotype-genotype correlations
2. Learn how to interact with the geneticist for molecular and genetic testing strategies, understand the use of different techniques for the detection of variants and how to determine their potential pathogenicity
3. Discuss the data generated by the next generation sequencing and their clinical use
4. Elaborate and anticipate genetic testing results or their absence in clinical practice according to international guidelines
ANS evaluation in peripheral nervous system dysfunctions
Vincenzo Donadio, BOLOGNA, ITALY

ANS evaluation in central nervous system dysfunctions
Christopher Mathias, LONDON, UK

ANS responses to stress
Mikael Elam, GOTHENBURG, SWEDEN

This workshop will address the diagnosis of autonomic dysfunctions by neurophysiological techniques. Autonomic dysfunctions involve protean clinical manifestation including cardiovascular, gastrointestinal, urogenital, thermoregulatory and pupillomotor symptoms and the diagnosis of these dysfunctions is an important clinical issue.

At the completion of this session, participants should be able to:
1. Recognize and diagnosis peripheral autonomic dysfunctions
2. Differentiate central from peripheral autonomic dysfunctions
3. Discuss the spectrum of abnormal autonomic reactivity to stress
FOCUSED WORKSHOP 8
GUT AND BRAIN IN PD AND MSA

Chairperson:
Carlo Colosimo, ROME, ITALY

Constipation: an emerging risk factor for PD?
Carlo Colosimo, ROME, ITALY

Diagnosis and management of gastrointestinal dysfunction in MSA and PD
Walter Struhal, LINZ, AUSTRIA

Alpha-synuclein propagation in PD: role of enteric nervous system pathology
Janice Houlton, LONDON, UK

At the completion of this session, participants should be able to:

1) To provide a critical summary of current evidence regarding constipation as an early disease marker versus true risk factor for PD
2) To address the various manifestations of GIT dysfunction and their state of the art treatment in MSA and PD focusing on constipation
3) To elucidate the evidence favouring enteric seeding and propagation of synuclein pathology to CNS sites in PD
INTERACTIVE SESSION 1
UPDATE ON VESTIBULAR DISORDERS

Chairperson:
Alexandre Bis dorff, ESCH SUR ALZETTE, LUXEMBURG

Functional vestibular anatomy and neuro-otologic bedside testing
Michael Strupp, MUNICH, GERMANY

Neuro-otology in the emergency room
Barry Seemungal, LONDON, UK

Diagnosis and treatment of vestibular migraine
Alexandre Bis dorff, ESCH SUR ALZETTE, LUXEMBOURG
HANDS-ON COURSE 1
NEUROPHYSIOLOGY I – BASIC

Chairperson:
Josep Valls-Sole, BARCELONA, SPAIN

Nerve conduction studies
Reinhard Dengler, HANNOVER, GERMANY

The study of reflexes in clinical practice
Josep Valls-Sole, BARCELONA, SPAIN

Up to 50 persons – Sold out!

This course is supported by Natus Medical Inc.
O1101 14:45  Parkinson bradykinesia correlates with EEG background frequency and perceptual forward projection in visual motion
M. Beudel, L. Roosma, O. Martinez Manzanera, T. van Laar, N. Maurits, B. de Jong
GRONINGEN, NETHERLANDS

O1102 15:00  Genetic variation in DRD3 and impulse control disorders in Parkinson’s disease
D. Boleixa, A. Gonçalves, A. Bettencourt, B. Leal, C. Carvalho, S. Brás, A. Mendes, N.M.D.S. Vila-Chá, J. Damasio, I. Moreira, J. Fernandes, P.P. Costa, S. Cavaco, B. Silva
PORTO, PORTUGAL

O1103 15:15  Prolonged release oxycodone/naloxone (OXN PR) for the treatment of severe Parkinson’s disease (PD)-related pain: a double-blind, randomised, placebo-controlled study
1LONDON, UNITED KINGDOM, 2TOULOUSE, FRANCE, 3 MADRID, SPAIN, 4 CAMBRIDGE, UNITED KINGDOM, 5LIMBURG, GERMANY, 6 KASSEL, GERMANY

O1104 15:30  The 22q11.2 microdeletion as a genetic cause to consider in case of early-onset Parkinson’s disease. B. Dufournet1, K. NGUYEN1, D. Grabli2, E. Broussolle3, S. Drapier4, M. Borg5, J.-L. Houeto6, C. Marelli Tosi7, L. Defebvre6, J.-P. Azulay1
1MARSEILLES, 2PARIS, 3LYONS, 4 RENNES, 5NICE, 6LILLE, 7 MONTPELLIER, FRANCE

O1105 15:45  A predictive metabolic marker of apathy following subthalamic nucleus deep brain stimulation in Parkinson’s disease
A. Eusebio, A. Gesquière-Dando, E. Guedj, R. Carron, A. Loundou, T. Witjas, F. Fluchère, J. Regis, J.-P. Azulay
MARSEILLES, FRANCE

O1106 16:00  Do late-stage Parkinson’s disease patients still respond to levodopa?
M. Fabbrri, M. Coelho, D. Abreu, L. Guedes, N. Gonçalves, M. Rosa, J. Ferreira
LISBON, PORTUGAL
ORAL SESSION: MS AND RELATED DISORDERS 1

Chairpersons:
Ralf Gold, BOCHUM, GERMANY
Hanne Flinstad Harbo, OSLO, NORWAY

O1107 14:45
Fifty years untreated prognosis of multiple sclerosis based on an incidence cohort
O. Andersen, B. Skoog, B. Runmarker, V. Lisovskaja, O. Nerman, H. Tedeholm
GOTENBURG, SWEDEN

O1108 15:00
Myelin regeneration improves clinical prognosis in multiple sclerosis: a longitudinal PET study with 11C-PIB
B. Bodini1, M. Veronese2, D. Garcia-Lorenzo1, M. Battaglini3, L. Freeman1, A.-C. Papeix1, B. Zalc1, M. Tchikviladze1, C. Lubetzki1, M. Bottlaender4, F. Turkheimer2, B. Stankoff1
1PARIS, FRANCE, 2LONDON, UNITED KINGDOM, 3SIENNA, ITALY, 4ORSAY, FRANCE

O1109 15:15
Long-term assessment of No Evidence of Disease Activity (NEDA) in patients with relapsing-remitting multiple sclerosis
N. De Stefano1, M.L. Stromillo1, A. Giorgio1, M.L. Bartolozzi2, M. Battaglini1, M. Baldini2, E. Portaccio3, M.P. Amato3, M.P. Sormani4
1SIENA, 2EMPOLI, 3FLORENCE, 4GENOA, ITALY

O1110 15:30
Long-term efficacy of delayed-release dimethyl fumarate in newly diagnosed patients with RRMS: an integrated analysis of DEFINE, CONFIRM, and ENDORSE
R. Gold1, G. Giovannoni2, J.T. Phillips3, R.J. Fox4, A. Zhang5, N.C. Kurukulasuriya5
1BOCHUM, GERMANY, 2LONDON, UNITED KINGDOM, 3DALLAS, USA, 4CLEVELAND, USA, 5CAMBRIDGE, USA

O1111 15:45
The effects of natalizumab and fingolimod on clinical, neuropsychological and MRI measures in relapsing remitting multiple sclerosis: a one-year comparative study
M.A. Rocca1, P. Preziosa1, G. Riccitelli1, M. Rodegher1, M. Copetti2, L. Moiola1, F. Mele1, A. Falini1, G. Comi1, M. Filippi1
1MILAN, 2SAN GIOVANNI ROTONDO, ITALY
O1112  36 months PANGAEA: a 5-year non-interventional study
16:00  of safety, efficacy and pharmacoeconomic data for fingolimod patients in daily clinical practice

T. Ziemssen¹, H. Albrecht², L. Klotz³, S. Schmidt⁴, H.-J. Schwarz², B. Tackenberg⁵, C. Cornelissen⁶
¹DRESDEN, ²MUNICH, ³MÜNSTER, ⁴BONN, ⁵MARBURG, ⁶NUREMBERG, GERMANY
Exome array GWAS in 10,000 Germans identifies association between MUC22 and multiple sclerosis

1MUNICH, 2LÜBECK, 3 AUGSBURG, 4 BOCHUM, 5HAMBURG, 6 DÜSSELDORF, 7 KIEL, 8 COLOGNE, 9 ERLANGEN, 10BONN, 11BERLIN, 12HANOVER, 13MARBURG, 14LEIPZIG, 15ULM, 16MÜNSTER, 17HEIDELBERG, 18ROSTOCK, 19 TÜBINGEN, 20MAINZ, GERMANY

First description of Leber’s hereditary optic neuropathy in association with the 3243A>G “MELAS” mutation in the mitochondrial DNA MTTL1 gene

C. Catarino1, C. Thiels2, C. Köhler2, T. Lücke2, T. Klopstock1
1MUNICH, 2BOCHUM, GERMANY

Familial dyskinesia with facial myokymia due to ADCY5 mutation: treatment with propranolol

C. Küpper, C. Gallenmüller, W. Müller-Felber, T. Haack, T.-M. Strom, T. Meitinger, T. Klopstock
MUNICH, GERMANY

Cognitive progression in patients with genetic forms of Parkinson’s disease treated with deep brain stimulation: a retrospective imaging genetics study

G. Mangone1, M.F. Cormier-Dequaire1, K. Tahiri1, J. Kraemmer1, M.-L. Weiter1, A. Walerant1, C. Karachi1, M.S. Navarro1, V. Guillemot1, A. Tenenhaus1, J. Gueguan1, V. Perlbarg1, S. Fernandez-Vidal1, D. Garcia-Lorenzo1, F. Gargouri1, S. Lehericy1, F. Pineau1, S. Lesage1, P. Pelissier1, A. Castrioto2, P. Krack2, C. Delaigue3, F. Durif3, A. Brice2, J.-C. Corvol1
1PARIS, 2GRENOBLE, 3CLERMONT-FERRAND, FRANCE
A four-year longitudinal study of postural stability and eye movements in premanifest subjects for spinocerebellar Ataxia type 1 and 2

L. Nanetti, D. Alpini, M. Panzeri, A. Castaldo, V. Mattei, C. Gellera, C. Mariotti

MILAN, ITALY

Mutation in O-linked N-acetylglucosaminetransferase (OGT) gene is associated with microcephaly, hypothyroidism, developmental delay, epilepsy, nystagmus and abnormal urine oligosaccharide pattern.

F. Serajee, A. Huq

DETROIT, USA
ORAL SESSION: NEUROTRAUMATOLOGY AND -REHABILITATION

Chairpersons:
Pieter Vos, NIJMЕGEN, NETHERLANDS
TBA

**O1119 14:45**  
Incidence of Headache in retired NFL players. Correlation with diffusion tensor MRI imaging and neuropsychological testing.  
F. Conidi  
STUART, USA

**O1120 15:00**  
Shaping early reorganization of neural networks promotes motor function after stroke  
L.J. Volz1, A.K. Rehme1, J. Michely1, C. Nettekoven2, S.B. Eickhoff3, G.R. Fink1, C. Grefkes1  
1COLOGNE, 2JUELICH, 3DUSSELDORF, GERMANY

**O1121 15:15**  
Network predictors of motor and language recovery after stroke  
A. Guggisberg, P. Nicolo, S. Rizk, A. Schnider  
GENEVA, SWITZERLAND

**O1122 15:30**  
Multimodal neuroimaging study of hand motor recovery prognosis in chronic ischemic stroke patients  
M. Nazarova1, M.A. Piradov1, P. Novikov1, R. Konovalov1, E. Blagovechtchenski1, V. Nikulin2  
1MOSCOW, RUSSIAN FEDERATION, 2BERLIN, GERMANY

**O1123 15:45**  
Brain functional changes after a somatosensory discrimination training in healthy young subjects  
E. Sarasso, F. Agosta, P. Adamo, F. Temporiti, A. Falini, R. Gatti, M. Filippi  
MILAN, ITALY

**O1124 16:00**  
Combining non-invasive brain stimulation (dual-tDCS) and motor skill learning induces a lasting increase of rs-fMRI functional connectivity in stroke patients  
Y. Vandermeeren1, L. Dricot2, P. Laloux1, P. Desfontaines3, F. Evrard4, A. Peeters2, J. Jamart1, S. Lefebvre1  
1YVOIR, 2BRUSSELS, 3LIEGE, 4OTTIGNIES, BELGIUM
ORAL SESSION:
PERIPHERAL NERVE DISORDERS 1

Chairpersons:
Isabel illa, BARCELONA, SPAIN
Jean Marc Leger, PARIS, FRANCE

O1125 14:45  Gene therapy with neurotrophic factors improved recovery after sciatic nerve injury in mice
F. Benninger¹, M. Glot¹, T. Ben-Zur¹, Y. Barhum¹, E. Kogan¹,
I. Steiner¹, D. Yaffe², D. Offen¹
¹PETACH TIKVA, ²REHOVOT, ISRAEL

O1126 15:00  Exome sequencing in a patient with Charcot-Marie-Tooth disease
G.J. Braathen, K. Tveten, H. Høyer, Ø.L. Holla, Ø.L. Busk
SKIEN, NORWAY

O1127 15:15  CMT genetic distribution in Spanish TREAT-CMT consortium
R. Sivera¹, C. Casasnovas², C. Marquez³,
S.I. Pascual Pascual⁴, M. Barrero¹, M.A. Alberti²,
C. Homedes², L. Villareal³, M. Garcia⁴,
J.F. Arpa Gutierrez⁴, J.F. Vázquez Costa¹, N. Muelas¹,
M.J. Chumillas¹, F. Palau¹, C. Espinos¹, T. Sevilla¹
¹VALENCIA, ²BARCELONA, ³SEVILLE, ⁴MADRID, SPAIN

O1128 15:30  Identification of a novel gene involved in Charcot-Marie-Tooth disease
R. Sivera, T. Sevilla, V. Lupo, P. Sancho, J.J. Vilchez,
F. Palau, C. Espinos
VALENCIA, SPAIN

O1129 15:45  Intraneural and intrathecal gene delivery using a Schwann cell targeted lentiviral vector for treating inherited demyelinating neuropathies
K. Kleopa, A. Kagiava, S. Bashardes, J. Richter,
C. Christodoulou, I. Sargiannidou
NICOSIA, CYPRUS

O1130 16:00  Rituximab is effective in treatment-resistant CIDP with IgG4 antibodies against paranodal proteins
L.A. Querol Gutierrez¹, R. Rajas-García¹, J. Diaz-Manera¹,
J. Barcena², J. Pardo Fernandez³, A. Ortega-Moreno⁴,
M.J. Sedano⁵, L. Sero-Ballesteros⁶, A. Carvajal⁶, N. Ortiz⁶,
E. Gallardo¹, I. Illa¹
¹BARCELONA, ²BILBAO, ³SANTIAGO DE COMPOSTELA,
⁴GRANADA, ⁵SANTANDER, ⁶REUS, SPAIN
ORAL SESSION: CLINICAL NEUROPHYSIOLOGY

Chairpersons:
Christian Krarup, COPENHAGEN, DENMARK
Josep Valls-Solé, BARCELONA, SPAIN

O1201 16:45
Effects of acetyl-DL-leucine on the cerebral activation pattern in cerebellar ataxia (FDG-PET study)
MUNICH, GERMANY

O1202 17:00
Modulation of cortico-cortical functional connectivity with intracerebral paired-pulses electrical stimulations
S. Boulogne, N. Andre-Obadia, P. Ryvlin, S. Rheims
LYONS, FRANCE

O1203 17:15
Comparison of motor cortex excitability in Progressive supranuclear palsy, Parkinson’s disease and healthy controls: a transcranial magnetic stimulation study
M. Fichera, E. Houdayer, F. Avantaggiato, R. Chieffo, G. Comi, M.A. Volonté, L. Leocani
MILAN, ITALY

O1204 17:30
Sensitivity of single fibre electromyography in ocular myasthenia
M.P. Giannoccaro, V. Donadio, V. di Stasi, P. Avoni, R. Liguori
BOLOGNA, ITALY

O1205 17:45
QEEG and apathy in patients with PD: alpha power changes in frontal and temporal regions
BASEL, SWITZERLAND

O1206 18:00
Correlation between electrodiagnostic features and genotype in Kennedy’s disease (SBMA): a study of a large population
M. Voippe1, G. Zara1, G. Querin1, C. Bertolin1, E. da Re1, F. Zoccarato1, E. Volpato1, D. Pareyson2, M. Ermani1, G. Soraru1
1PADUA, 2MILAN, ITALY
ORAL SESSION:
MOVEMENT DISORDERS 2

Chairpersons:
Joaquim Ferreira, LISBON, PORTUGAL
Antonella Macerollo, BARI, ITALY

O1207 16:45
Congenital pyramidal signs and cerebellar ataxia with abnormal pyramidal decussation – a new syndrome
LISBON, PORTUGAL

O1208 17:00
Motor, non-motor and cognitive features in idiopathic REM sleep behaviour disorder mirror those observed in Parkinson’s disease
M. Rolinski1, N. Zokaei1, M. Lawton2, S. Evetts1, F. Baig1, C. Ruffman1, C. Mackay1, T. Quinnell1, Z. Zaiwalla1, Y. Ben-Shlomo2, M. Husain1, M. Hu1
1OXFORD, 2BRISTOL, 3PAPWORTH, UNITED KINGDOM

O1209 17:15
Widespread functional, but not structural, changes in patients with idiopathic REM sleep behaviour disorder
M. Rolinski1, L. Griffanti1, K. Szewczyk-Krolakowski1, R. Menke1, T. Quinnell1, Z. Zaiwalla1, C. Mackay1, M. Hu1
1OXFORD, 2PAPWORTH, UNITED KINGDOM

O1210 17:30
Discrimination in dystonia: time for a rethink?
A. Sadnicka1, C. Daum1, S. Manohar2, J. Rothwell1, M. Edwards1
1LONDON, 2OXFORD, UNITED KINGDOM

O1211 17:45
Brain plasticity after implanted drop foot stimulator in chronic stroke
A. Thibaut1, O. Gosseries2, S. Laureys3
1BELGIUM, 2MADISON, USA, 3LIEGE, BELGIUM

O1212 18:00
Evolution of mild parkinsonian motor signs in a longitudinal population-based cohort
S. Tunc1, J. Hamp1, J. Graf1, E.-J. Vollstedt1, V. Tadic1, E. Warriich1, C. Bibergeil1, N. Bruggemann1, J. Hagenah2, C. Klein1, M. Kasten1
1LÜBECK, 2HEIDE, GERMANY
ORAL SESSION:
MS AND RELATED DISORDERS 2

Chairpersons:
Maria Trojano, BARI, ITALY
Slavica Vujisic, PODGORICA, MONTENEGRO

O1213 16:45
Feasibility and effectiveness of home-based, computerised cognitive rehabilitation in multiple sclerosis - a functional MRI study
J. Campbell¹, M. Cercignani², D. Langdon², W. Rashid¹
¹BRIGHTON, ²LONDON, UNITED KINGDOM

O1214 17:00
Neuroprotection with phenytoin in acute optic neuritis: results of a phase II randomised controlled trial.
R. Raftopoulos¹, S. Hickman², A. Toosy¹, B. Sharrack², S. Mallik¹, D. Altmann¹, P. Malladi¹, M. Koltzenburg¹, C. Wheeler-Kingshott¹, K. Schmierer¹, G. Giovannoni³, D. Miller¹, R. Kappor¹
¹LONDON, ²SHEFFIELD, UNITED KINGDOM

O1215 17:15
Rate of brain volume loss under long-term delayed-release dimethyl fumarate treatment in relapsing-remitting multiple sclerosis patients: results from the ENDORSE study
L. Kappos¹, R.J. Fox², R. Gold³, D.L. Arnold⁴, J. Potts⁵, A. Zhang⁵, N.C. Kurukulasuriya⁵
¹BASEL, SWITZERLAND, ²CLEVELAND, USA, ³BOCHUM, GERMANY, ⁴MONTREAL, CANADA, ⁵CAMBRIDGE, USA

O1216 17:30
Effect of MD1003 (high doses of biotin) in progressive multiple sclerosis: results of a pivotal phase III randomised double blind placebo controlled study
A. Tourbah¹, C. Lebrun-Frenay², G. Eden³, M. Clanet⁴, A.-C. Papeix⁵, S. Vukusic⁶, J. de Seze⁷, M. Debouverie⁸, O. Gout⁹, P. Clavelou¹⁰, G.L. Defer¹¹, D. Laplaud¹², T. Moreau¹³, P. Labauge¹⁴, B. Brochet¹⁵, M. M.F. Sedel¹⁵, J. Pelletier¹⁶
¹RHEIMS, ²NICE, ³RENNES, ⁴TOULOUSE, ⁵PARIS, ⁶LYONS, ⁷STRASBOURG, ⁸NANCY, ⁹PARIS, ¹⁰CLERMONT-FERRAND, ¹¹CAEN, ¹²NANTES, FRANCE, ¹³DIJON, ¹⁴MONTPELLIER, ¹⁵BORDEAUX, ¹⁶MARSEILLES, FRANCE
Oral Session: MS and related disorders 2 (condt.)

Chairpersons:
Maria Trojano, BARI, ITALY
Slavica Vujisic, PODGORICA, MONTENEGRO

O1217 17:45  A randomized, blinded, parallel-group phase-2 study exploring the efficacy, safety, and tolerability of multiple natalizumab dosing regimens in patients with relapsing multiple sclerosis (REFINE)
M. Trojano¹, L. Ramió-Torrentó², L.M.E. Grimaldi³, C. Lubetzki⁴, S. Schippling⁵, K. Evans⁶, S. Gheuens⁶, K. Muralidharan⁶, A. Natarajan⁶, D. Mikol⁶¹BARI, ITALY, ²GIRONA, SPAIN, ³CEFALÙ, ITALY, ⁴PARIS, FRANCE, ⁵ZURICH, SWITZERLAND, ⁶CAMBRIDGE, USA

O1218 18:00  Daclizumab High-Yield Process (DAC HYP) vs. interferon beta-1a in patients with highly active disease: DECIDE study results
H. Wiendl¹, L. Kappos², K. Selmaj³, E. Havrdova⁴, J. Rose⁵, K. Riester⁶, L.C. Tsac⁷, S. Greenberg⁷, J. Elkins⁸¹MUNSTER, GERMANY, ²BASEL, SWITZERLAND, ³LODZ, POLAND, ⁴PRAGUE, CZECH REPUBLIC, ⁵SALT LAKE CITY, USA, ⁶CAMBRIDGE, USA, ⁷REDWOOD CITY, USA
ORAL SESSION:
NEURO-OPHTHALMOLOGY/-OTOLOGY

Chairpersons:
Marianne Dieterich, MUNICH, GERMANY
TBA

O1219 16:45
Using transcranial magnetic stimulation (TMS) to probe effects of visual motion adaptation on primary visual cortex (V1) excitability in bilateral vestibular failure patients
H. Ahmad, R. Roberts, M. Patel, Q. Arshad, A. Bronstein
LONDON, UNITED KINGDOM

O1220 17:00
Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography
P. Albrecht1, C. Blasberg1, S. Lukas2, M. Ringelstein1, A.-K. Müller1, E.-M. Kados3, D. Finis1, R. Guthoff1, Q. Aktas1, H.-P. Hartung1, F. Paul3, A. Brandt3, P. Berlit4, A. Methner5, M. Krämer4
1DÜSSELDORF, GERMANY, 2ZURICH, SWITZERLAND, 3BERLIN, 4ESSEN, 5MAINZ, GERMANY

O1221 17:15
Retina examination in neurodegenerative diseases
U.A. Kayabasi1, R.C. Sergott2
1ISTANBUL, TURKEY, 2PHILADELPHIA, USA

O1222 17:30
What is post-concussion dizziness?
Expert neuro-otological assessment in acute Traumatic Brain Injury (TBI)
LONDON, UNITED KINGDOM

O1223 17:45
A novel diagnostic tool for myasthenia gravis: ocular vestibular evoked myogenic potentials (oVEMP)
Y. Valkö1, S. Rosengren2, H. Jung3, D. Straumann1, K. Landau1, K. Weber1
1ZURICH, SWITZERLAND, 2SYDNEY, AUSTRALIA

O1224 18:00
Anti-compensatory saccades as an indicator of peripheral vestibular function in a new complementary video head impulse test paradigm
H.G. MacDougall1, L.A. McGarvie4, G.M. Halmagyi1, S.J. Rogers1, L. Manzari2, A.M. Burgess1, I.S. Curtoys4, K.P. Weber3
1SYDNEY, AUSTRALIA, 2CASSINO, ITALY, 3ZURICH, SWITZERLAND
SATURDAY, JUNE 20, 2015
16:45-18:15

ORAL SESSION: SLEEP DISORDERS

Chairpersons:
Claudio Bassetti, BERN, SWITZERLAND
Pierre Maquet, LIÈGE, BELGIUM

O1225 16:45  Post tick-borne encephalitis (TBE) vaccination narcolepsy-cataplexy
H. Hidalgo Pareja1, J. Mathis2, C. Bassetti2, U. Kallweit2
1KATZENELNBÖGEN, GERMANY, 2BERNE, SWITZERLAND

O1226 17:00  PDSS-2 cut-off scores for the severity of sleep disturbances in PD patients
M.-L. Muntean1, H. Benes2, F. Sixel-Döring1, C. Trenkwalder1
1KASSEL, GERMANY, 2SCHWERIN, GERMANY

O1227 17:15  Narcolepsy Type-1 and idiopathic generalized epilepsy: diagnostic and therapeutic challenges in dual cases.
S. Baiardi1, S. Vandi1, L. Alvisi1, F. Pizza1, L. Toscani2, E. Zambrelli3, P. Tinuper1, R. Liguori1, G. Piazz1
1BOLOGNA, 2FLORENCE, 3MILAN, ITALY

O1228 17:30  Obstructive sleep apnoea (OSA) and circadian variation in the timing of stroke onset
D. Sangalli, B. Corrà, L. Adobbati, P. Mattaliano, C. Lombardi, G. Parati, V. Silani
MILAN, ITALY

O1229 17:45  Restless legs syndrome patients have higher values of nocturnal systolic blood pressure
M. Sieminski1, M. Partinen2
1GDANSK, POLAND, 2HELSINKI, FINLAND

O1230 18:00  Performance decline during chronic sleep deprivation is associated with decreasing cerebral oxygen level in adolescents under real-life school conditions
Z. Zhang1, C. Lienhard2, Y. Kindler2, M. Qi1, G. Hügli1, R. Khatami1
1BARMELWEID, 2AARAU, SWITZERLAND
This course will provide current and updated information about a range of issues in stroke management and treatment. The current treatment of acute ischemic and hemorrhagic stroke will be discussed as well as secondary stroke prevention and unique issues of young stroke management.

The course will include the most updated information including recent results of RCTs and current guidelines on the topics.
Valproate and pregnancy: update and new EMA guidance
Torbjörn Tomson, STOCKHOLM, SWEDEN

Rituximat or other MAPs: why, where, when and how outside of MS: how to use these drugs, and when. Side effects
Gavin Giovannoni, LONDON, UK

Stroke: stent retriever in cerebral artery occlusions
Alain Bonafé, MONTPELLIER, FRANCE

Neuroprosthetics
Alireza Gharabaghi, TUBINGEN, GERMANY

Text fehlt
TEACHING COURSE 3
NEW ADVANCES IN THE TREATMENT OF IMMUNE MEDIATED NEUROPATHIES – LEVEL 3

Chairperson:
Eduardo Nobile-Orazio, MILAN, ITALY

Guillain-Barré syndrome:
Pieter van Doorn, ROTTERDAM, THE NETHERLANDS

Chronic inflammatory demyelinating polyradiculoneuropathy
Peter Van den Bergh, BRUSSELS, BELGIUM

Multifocal motor neuropathy
Eduardo Nobile-Orazio, MILAN, ITALY

Paraproteinemic neuropathy
Jean-Marc Léger, PARIS, FRANCE

This course will be held in cooperation with the Peripheral Nerve Society (PNS).

This course is designed for trainees or practitioners wishing to update and develop their knowledge in the treatment of immune mediated neuropathies. The speakers will initially address when to start treatment in these neuropathies and will subsequently review the data from the most recent trials and reviews on their treatment. The cost–utility aspect will be addressed, including an analysis of the cost and potential adverse events of these therapies. The long–term treatment and the approach in patients not responsive to initial treatment will be also addressed. At the end of the course, participants will improve their capacities in the therapeutic approach to these neuropathies.
Diagnosis of amyotrophic lateral sclerosis (ALS) is considered difficult by many neurologists. However, recent progress, in particular with regard to differential diagnosis, has made it a comparatively easy diagnosis which can be done in early stages. The knowledge of clinical phenotypes was refined during the past decades; MRI is a valuable aid in differential diagnosis, the same as true for clinical neurophysiology. Genetics contributes to the diagnosis, but also adds some ambiguities. Since the relation of ALS and frontotemporal dementias is now widely accepted, there is an increasing role of neuropsychology.
TEACHING COURSE 5
EPILEPSY - BASIC APPROACH TO A SEIZING PATIENT – LEVEL 1

Chairperson:
Erik Tauboll, OSLO, NORWAY

Clinical, EEG and imaging diagnosis of epileptic seizures
Milan Brazdil, BRNO, CZECH REPUBLIC

Aetiologies of seizures in clinical practice
Erik Tauboll, OSLO, NORWAY

Rational choice of antiepileptic drugs
Elinor Ben-Menachem, GOTHENBURG, SWEDEN

When to start (and stop) antiepileptic drugs?
Tony Marson, LIVERPOOL, UK
Aging populations around the globe represent major challenges for society and healthcare systems. Brain health plays a major role in maintaining wellbeing as we age. This teaching course covers recent advancements in multiple areas of brain aging. Topics include psychological aspects, the measurement of brain aging using neuroimaging techniques as well as genetic and cellular aspects that facilitate our understanding of brain aging and might provide targets for future interventions.
88. Kongress der Deutschen Gesellschaft für Neurologie mit Fortbildungsakademie
23. – 26. September 2015
Düsseldorf

Online-Programm und Anmeldung unter: www.dgnkongress.org

Besuchen Sie uns am Stand B52!
HANDS-ON COURSE 2
NEUROPHYSIOLOGY II – BASIC

Chairperson:
Christian Krarup, COPENHAGEN, DENMARK

Electromyography - conventional
Christian Krarup, COPENHAGEN, DENMARK

Electromyography – single fibre
Sanjeev Nandedkar, HOPEWELL JUNCTION, USA

This course is supported by Natus Medical Inc.

Sold out!
PRESIDENTIAL PLENARY SYMPOSIUM:
HOT TOPICS IN NEUROLOGICAL SCIENCES

Chairpersons:
Günther Deuschl, KIEL, GERMANY
Wolfgang Oertel, MARBURG, GERMANY

Translational research for biomarkers in multiple sclerosis
Xavier Montalban, BARCELONA, SPAIN

The concept of hypo- and hyperdopaminergic dysfunction of the basal ganglia
Jens Volkmann, WÜRZBURG, GERMANY

Immunisation strategies for neurodegenerative disease
Bruno Dubois, PARIS, FRANCE

Biomarkers for epilepsy. What is becoming clinically useful?
Annamaria Vezzani, MILAN, ITALY
Dementias with parkinsonism have been primarily associated with synuclein pathology, including Lewy body dementia spectrum and multisystem atrophy, and tau pathology, including Frontotemporal Degeneration (FTD) with parkinsonism linked to mutations in Microtubule Associated Protein Tau (MAPT), known as FTDP-17, Progressive Supranuclear Palsy and Corticobasal Degeneration. Nevertheless, recent findings demonstrated that parkinsonism often occur also in FTD patients carrying mutations in progranulin gene (GRN) or in the Chromosome 9 Open Reading Frame (C9ORF)72 gene, both of which are instead associated with the deposition of TAR DNA Binding Protein (TDP)-43 in the brain. Here, these disorders will be discussed, including clinical presentation, genetics, molecular mechanisms involved in their pathogenesis, and management.
Early and tailor-made treatment aimed at reducing the risk of future cardiovascular complications is of utmost importance for patients who suffered from a transient ischaemic attack or minor ischaemic stroke. Many trials have been conducted during the previous decades that can support the clinician in making the most appropriate choice for this, but we do not have evidence based therapies for every patient. In this workshop the state of the art of secondary prevention will be presented in the context of medical, surgical, endovascular, and cardiac interventions. Both treatment options of proven and of unproven value will be discussed.
FOCUSED WORKSHOP 11
EPILEPSY IN GLIOMAS

Chairperson:
Anja Smits, UPPSALA, SWEDEN

Epidemiology and prognostic importance of seizures
Anja Smits, UPPSALA, SWEDEN

The role of surgery to control seizures
Hugues Duffau, MONTPELLIER, FRANCE

The impact of radiation, chemotherapy and AEDs on seizures
Roberta Rudà, TURIN, ITALY

The goal of this focused workshop is to give an update on tumour-related seizures that is of interest to clinicians including practical aspects of treatment, to give an insight into the underlying mechanisms of seizures and brain tumours, and to highlight current research questions.
FOCUSED WORKSHOP I2
RNA-RELATED NEUROLOGICAL DISORDERS AND RNA INTERFERENCE IN THERAPY

Chairperson:
Derick G. Wansink, NIJMEGEN, THE NETHERLANDS

Non-coding and microRNA as anti-epileptogenic treatment targets
David Henshall, DUBLIN, IRELAND

ALS
Nicola Ticozzi, MILAN, ITALY

RNA-directed therapy
Derick G. Wansink, NIJMEGEN, THE NETHERLANDS

RNA has taken center stage in the pathology of a subset of neurological disorders. The first objective of this workshop is to provide insight in the pathophysiology of neurological diseases characterized by abnormal expression of transcripts (e.g. miRNAs, repeat RNAs). As expression of these RNAs is strongly related to disease development, they constitute logical targets for intervention. Hence, the second objective is to discuss therapeutic strategies for RNA-related neurological disorders, biotechnological therapeutics needed, and pros and cons associated with these approaches. Innovative ideas on how these strategies can be brought a step closer to the clinic are welcomed.
FOCUSED WORKSHOP 13
NEUROSTIMULATION IN PAROXYSMAL NEUROLOGICAL DISORDERS

Chairperson:
Delphine Magis, LIÈGE, BELGIUM

Invasive neurostimulation in migraine and cluster headache
Tim Jürgens, HAMBURG, GERMANY

Neurostimulation in epilepsy
Paul Boon, GHENT, BELGIUM

Non-invasive neuromodulation in headache: new targets and indications
Delphine Magis, LIÈGE, BELGIUM

The aim of this workshop is to provide a complete but practical overview of existing invasive and non-invasive neuromodulation methods used in the management of 2 frequent paroxysmal neurological disorders: headache and epilepsy. Besides the different types of devices and their availability, the audience will learn the peripheral and central targets of these therapies with their respective rationale, as well as the results of the most recent clinical studies, allowing a direct application in daily clinical practice.
Neuromuscular disorders are an important part of specialist neurointensive care practice, and neuromuscular complications are frequently the reason for neurological consults in general intensive care units (ICU). They comprise a wide variety of diverse and sometimes rare disorders, but often carry an excellent prognosis with optimal treatment.

This workshop focuses on some of the main categories of neuromuscular disease seen in the ICU with an emphasis on new developments in treatable disease. The speakers are world experts in their areas and will be based around case vignettes in order to illustrate new pathophysiological understanding, treatment principles and current best practice in a selection of major topics in neuromuscular disorders in Intensive Care. The aim of the workshop is to give an overview of new diagnostic and treatment concepts, and provide guidelines for management, which attendees can use in their daily practice.
Increasing prevalence of neurological morbidities from complications of pharmacotherapy pose significant challenges in clinical practice. These complications are often predictable or potentially reversible after treatment withdrawal, but there are also examples of neurological iatrogenesis in modern era that were unpredictable. This focused workshop presents three diverse but important examples of iatrogenic complications, due to contaminated methylprednisolone, immunological reactions of pharmacotherapy and from unregulated use of medicinal products. The key educational objectives are:

- Increased awareness of selected neurological syndromes due to iatrogenesis
- Lessons that have been learnt
- Anticipation and prevention of future risks
FOCUSED WORKSHOP 16
TAKING A NEUROLOGICAL SLEEP HISTORY

Chairperson:
Claudio Bassetti, BERN, SWITZERLAND

How to take a sleep history
Claudio Bassetti, BERN, SWITZERLAND

When should we use sleep questionnaires and how?
Dieter Riemann, FREIBURG, GERMANY

What sleep test and when should we ask for it?
Poul Jennum, COPENHAGEN, DENMARK
What is easily misinterpreted in neurological examination
Chris Constantinescu, NOTTINGHAM, UK

What is easily misinterpreted in radiological exams
Massimo Filippi, MILAN, ITALY

What is easily misinterpreted in clinical neurophysiology
Alain Maertens de Noordhout, LIÈGE, BELGIUM

What is easily misinterpreted in blood & CSF tests
Hayrettin Tumani, ULM, GERMANY
This course offers updates and reviews about clinically relevant applications of vascular ultrasound in stroke and circulatory arrest. Examinations during the acute phase of stroke disclose the variability of the occlusional and hemodynamic status immediately after disease onset. Unique selling points of ultrasound such as high temporal and spatial resolution which are clinically relevant for online monitoring and imaging will be presented. Emphasis is focused on practical aspects and there will be ample opportunity for discussion with leading experts in the field.

Sold out!
TOURNAMENT CLINICAL

Chairpersons:
Valeria Caso, PERUGIA, SPAIN
TBA
Nils Erik Gilhus, BERGEN, NORWAY

T2101 14:45 Safety of pregnancy following cerebral venous thrombosis (ISCVT2 - PREGNANCY)
D. Aguiar de Sousa1, P. Canhao1, I. Crassard2, J. Coutinho3, A. Arauz4, A. Conforto5, M. Gioud6, J.M.M.C. Ferro1
1LISBON, PORTUGAL, 2PARIS, FRANCE, 3AMSTERDAM, NETHERLANDS, 4MEXICO CITY, MEXICO, 5SÃO PAULO, BRAZIL, 6DIJON, FRANCE

T2102 15:00 Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: a multicenter study
A. Bisecco1, M.A. Rocca1, E. Pagan1, L. Mancini2, C. Enzinger3, A. Gallo4, H. Vrenken5, M.L. Stromillo6, M. Copetti7, D. Thomas2, F. Barkho5, N. De Stefano6
1MILAN, ITALY, 2LONDON, UNITED KINGDOM, 3GRAZ, AUSTRIA, 4NAPLES, ITALY, 5AMSTERDAM, NETHERLANDS, 6SIENNA, ITALY, 7SAN GIOVANNI ROTONDO, ITALY

T2103 15:15 Antibodies to MOG in patients with a first episode of longitudinally extensive transverse myelitis: clinical implications
A. Cobo1, M. Sepulveda1, R. Bernard-Valnet1, A. Ruiz3, D. Brassat5, S. Martinez-Yelamos1, A. Saiz1, R. Marignier3
1BARCELONA, SPAIN, 2TOULOUSE, FRANCE, 3LYONS, FRANCE

T2104 15:30 Sensory attenuation and Parkinson’s disease: a new pathophysiological framework of bradykinesia
LONDON, UNITED KINGDOM

T2105 15:45 Corticospinal reserve predicts walking impairment but not fatigability in progressive multiple sclerosis
A. Nuara, R. Chieffo, F. Esposito, F.G. Martinelli Boneschi, M. Comola, G. Comi, L. Leocani
MILAN, ITALY

T2106 16:00 Insufficient global health education in European post-graduate training: an EAYNT survey
A. Sauerbier1, A. Macerollo2, O. Gyorfi3, P. Balicza3, M. Moaracs4, V. Papp5, P. Zis6, L. Klingelhofer7, T. Saifee1, W. Struhal8, J. Sellner9
1LONDON, UNITED KINGDOM, 2BARI, ITALY, 3BUDAPEST, HUNGARY, 4BRASOV, ROMANIA, 5HOLSTEBRO, DENMARK, 6ATHENS, GREECE, 7DRESDEN, GERMANY, 8LINZ, AUSTRIA, 9SALZBURG, AUSTRIA
Endothelial and neuronal NOX4 is a key mediator of oxidative stress and neurodegeneration after focal cerebral ischemia in mice
E. Göb, H. H. Schmidt, C. Kleinschnitz
Würzburg, Germany
Maastricht, The Netherlands

Depressive symptoms in cerebral small vessel disease are associated with white matter microstructural damage: the VMCI-Tuscany study.
Florence, Italy
Rome, Italy
Bologna, Italy

White matter hyperintensities may be related to brain swelling in early cerebral small vessel disease
Paris, France
Graz, Austria
Saclay, France
Munich, Germany

Vasoreactive response to hyperemia in CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) patients
Florence, Italy
Genoa, Italy
Sienna, Italy
Cosenza, Italy

Influence of neurologists’ experience on the outcome of patients treated with intravenous thrombolysis for cerebral ischaemia.
A. Tuffal, D. Leys
Lille, France

Migraine prevalence in patients with unruptured intracranial aneurysms
E. Witvoet, N. Pelzer, G. Terwindt, G. J. Rinkel, M. Vlak, A. Algra, M. J. Wermer
Leiden, The Netherlands
Utrecht, The Netherlands
Amsterdam, The Netherlands

ORAL SESSION I HALL A1

SUNDAY, JUNE 21, 2015
14:45-16:15

ORAL SESSION CEREBROVASCULAR DIS EASES 1

Chairpersons:
Michael Brainin, Krems, Austria
Matthias Endres, Berlin, Germany
ORAL SESSION

EPILEPSY 1

Chairpersons:
Hannah Cock, LONDON, UNITED KINGDOM
Kristl Vonck, GHENT, BELGIUM

O2107
14:45
The treatment of Rett syndrome with NNZ-2566
A. Yaroshinsky5, O. Imas6, K.G. Jordan7, P. Stein8,
L. Glass8, N.E. Jones10, J. Horrigan11
1HOUSTON, USA, 2SAN DIEGO, USA, 3BIRMINGHAM, USA,
4ST. PAUL, USA, 5ROLLING MEADOWS, USA, 6MILWAUKEE, USA,
7REDLANDS, USA, 8ST. LOUIS, USA, 9WASHINGTON D.C., USA,
10BIRMINGHAM, UNITED KINGDOM, 11CHAPEL HILL, USA

O2108
15:00
Is clonazepam an effective alternative as a first line
agent for status epilepticus management?
V. Alvarez1, J.W. Lee2, F.W. Drislane2, M.B. Westover2,
J. Novy3, B.A. Dworetzky2, A.O. Rossetti3
1SION, SWITZERLAND, 2BOSTON, USA, 3LAUSANNE,
SWITZERLAND

O2109
15:15
The role of toll-like receptor 3 in epilepsy
F. Benninger1, A. Gross2, I. Steiner1, D. Offen1, E. Okun2
1PETACH TIKVA, ISRAEL, 2RAMAT GAN, ISRAEL

O2110
15:30
Eslicarbazepine acetate as add-on treatment to
antiepileptic monotherapy in adults with partial-onset
seizures: real-world data from the EPOS study
M. Holtkamp1, R. McMurray2, R. Sousa3, E. Kockelmann4
1BERLIN, GERMANY, 2HATFIELD, UNITED KINGDOM, 3S. MAMEDE
DO CORONADO, PORTUGAL, 4FRANKFURT AM MAIN, GERMANY

O2111
15:45
Register for collecting and measuring outcomes of
licensed anti-epileptic drugs in patients with epilepsy
and intellectual disability and/or pervasive
developmental disorders
R. Shankar1, Z. Doran1, B.N. McLean2, M.C. Walker4,
L.J. Sander4, D. Cox1, R. Hillier5, M.J. Sadler2, M. Mohan6,
M. Parrett1, C. Jory1, M. Kerr7, J. Devapriam6, J. Craig3,
R. Laugharne10
1TRURO, UNITED KINGDOM, 2PLYMOUTH, 3TRURO, 4LONDON,
5UNITED KINGDOM, 6BRISTOL, UNITED KINGDOM, 7CARDIFF,
UNITED KINGDOM, 8LEICESTERSHIRE, UNITED KINGDOM,
9BELFAST, 10LISKEARD, UNITED KINGDOM
Efficacy of adjunctive perampanel in idiopathic generalised epilepsy patients with drug-resistant primary generalised tonic-clonic seizures by age, sex, race: a double-blind PBO-controlled Phase 3 trial

B. J. Steinhoff¹, T. J. O’Brien², H. Yang², A. Laurenza³, A. Patten⁴, F. Bibbiani⁵

¹KEHL-KORK, GERMANY, ²MELBOURNE, AUSTRALIA, ³WOODCLIFF LAKE, NJ, USA, ⁴HATFIELD, HERTFORDSHIRE, UNITED KINGDOM

O2112
16:00
ORAL SESSION I HALL A6

SUNDAY, JUNE 21, 2015
14:45-16:15

ORAL SESSION

MOVEMENT DISORDERS 3

Chairpersons:
Marie Vidailhet, PARIS, FRANCE
Heinz Reichmann, DRESDEN, GERMANY

O2113 14:45 White matter microstructural damage and cognitive impairment in Parkinson’s disease
S. Galantucci1, F. Agosta1, D. Gagliardi1, I. Stankovic2, I. Petrovic2, F. Caso1, T. Stojkovic2, V.S. Kostic2, M. Filippi1
1MILAN, ITALY, 2BELGRADE, SERBIA

O2114 15:00 Pharmacokinetic profile of ND0612 (levodopa/carbidopa) for subcutaneous infusion in Parkinson’s disease (PD) patients with motor fluctuations: results of a Phase IIa dose finding study
N. Giladi1, Y. Caraco2, T. Gurevich1, R. Djaldetti1, Y. Cohen3, O. Yacobi-Zeevi3, S. Oren3, K. Kieburtz4, C.W. Olanow5
1TEL AVIV, ISRAEL, 2JERUSALEM, ISRAEL, 3REHOVOT, ISRAEL, 4ROCHESTER, USA, 5NEW YORK, USA

O2115 15:15 Apathy in Parkinson’s disease is associated with reward sensitivity deficits
K. Muhammed, S. Manohar, G. Tofaris, M. Bogdanovic, G. Lennox, M. Hu, M. Husain
OXFORD, UNITED KINGDOM

O2116 15:30 Nigral iron susceptibility in Parkinson’s disease
1LONDON, 2LONDON, UNITED KINGDOM, 3CAMBRIDGE, UNITED KINGDOM, 4LUND, SWEDEN

O2117 15:45 Idiopathic RBD patients express the Parkinson’s disease related brain pattern
1GRONINGEN, NETHERLANDS, 2MARBURG, GERMANY, 3AACHEN, GERMANY, 4HEEZE, NETHERLANDS

O2118 16:00 Multimodal MRI markers discriminate Parkinson’s disease from multiple system atrophy patients.
P. Péran1, M. Sierra2, A. Pavy-Le Traon1, O. Rascol1
1TOULOUSE, FRANCE, 2SANTANDER, SPAIN
ORAL SESSIONS | HALL M1

SUNDAY, JUNE 21, 2015

14:45-16:15

ORAL SESSION
NEURO-ONCOLOGY

Chairpersons:
Wolfgang Grisold, VIENNA, AUSTRIA
Riccardo Soffietti, TORINO, ITALY

O2119 14:45
Recursive partitioning analysis of WHO grade II, III and IV gliomas using 3121 samples
A. Alentorn, V. Gleize, M. Gleize, Y. Marie, J.-Y. Delattre, A. Idaih, K. Hoang-Xuan, M. Sanson
PARIS, FRANCE

O2120 15:00
Detection, characterization and inhibition of FGFR-TACC fusions in IDH wild type glioma
1PARIS, FRANCE, 2NEW YORK, USA, 3TITUSVILLE, USA, 4BARCELONA, SPAIN, 5MILAN, ITALY, 6VANCOUVER, CANADA, 7MONTREAL, CANADA, 8CALGARY, CANADA

O2121 15:15
Second-line chemotherapy with bevacizumab and fotemustine in temozolomide-pretreated patients with recurrent grade III gliomas: a phase II study
F. Franchino, M. Magistrello, A. Pellerino, E. Trevisan, R. Rudà, R. Soffietti
TURIN, ITALY

O2122 15:30
IL10 and IL10:IL6 ratio in CSF is useful for diagnosis but also in the assessment of therapeutic response in patients with Primary Central Nervous System Lymphoma (PCNSL)
L. Nauyen Them1, M. Costopoulos1, M.-L. Tanguy1, C. Houillier1, S. Choquet1, K. Hoang-Xuan1, M. Le Garff Tavernier1, C. Soussain2
1PARIS, FRANCE, 2SAINT CLOUD, FRANCE

O2123 15:45
Efficacy and tolerability of lacosamide in patients with glioma: a prospective study
A. Pellerino, M. Magistrello, F. Franchino, E. Nicolotto, R. Soffietti, R. Rudà
TURIN, ITALY

O2124 16:00
Incidence of radiation-induced leukoencephalopathy after radiation therapy in long-term survivors of WHO grade III and IV gliomas and risk factors
PARIS, FRANCE
ORAL SESSION  
**EPILEPSY 2**

Chairpersons:
Paul A.J.M. Boon, GHENT, BELGIUM
Reetta Kälviainen, KUOPIO, FINLAND

---

**O2201  16:45**  Early misdiagnosis of the etiology of status epilepticus (SE)  
F. Drislane¹, V. Alvarez², J.W. Lee¹, B.A. Dworetzky¹, M.B. Westover¹, D. Curley¹, A.O. Rossetti³  
¹BOSTON, USA, ²SION, SWITZERLAND, ³LAUSANNE, SWITZERLAND

**O2202  17:00**  Bilateral anterior nuclei of the thalamus stimulation for the treatment of epilepsy. Two cases of subcortical band heterotopia  
LISBON, PORTUGAL

**O2203  17:15**  Myocyte-specific enhancer binding factor 2A expression is downregulated during temporal lobe epilepsy  
Y. Jinxian, H. Yunyi, C. Yangmei, H. Hao  
CHONGQING, CHINA

**O2204  17:30**  Expression of miR146-a, an inflammation-associated microRNA, in Mesial Temporal Lobe Epilepsy  
PORTO, PORTUGAL

**O2205  17:45**  Retrospective evaluation of Salzburg Consensus criteria for diagnosis of non-convulsive status epilepticus  
M. Leitinger¹, G. Kuchukhidze¹, J. Höfler¹, J. Dobesberger¹, A. Rohracher¹, G. Kaliss¹, I. Deak¹, M. Preisel¹, E. Trinka¹, S. Beniczky²  
¹SALZBURG, AUSTRIA, ²DIANALUND, DENMARK
ORAL SESSION
HEADACHE AND PAIN

Chairpersons:
Rigmor Jensen, COPENHAGEN, DENMARK
Elena Lebedeva, YEKATERINBURG, RUSSIAN FEDERATION

O2206  16:45  Brief intervention for medication-overuse headache in primary care (the BIMOH study): an open long-term follow-up
E.S. Kristoffersen1, J. Straand2, M.B. Russell1,
C. Lundqvist1
1LØRENSKOG, NORWAY, 2OSLO, NORWAY

O2207  17:00  Quality of diagnosis and management of headache in the general population
E. Lebedeva1, N. Kobzeva1, D. Gilev1, J. Olesen2
1YEKATERINBURG, RUSSIAN FEDERATION, 2COPENHAGEN, DENMARK

O2208  17:15  Structural cortical brain abnormalities in patients with vestibular migraine
R. Messina, M.A. Rocca, B. Colombo, R. Teggi, A. Falini,
G. Comi, M. Filippi
MILAN, ITALY

O2209  17:30  Nigrostriatal dopaminergic system involvement in the primary burning mouth syndrome: a transcranial sonography study
M. Mijajlovic, J. Zidverc-Trajkovic, N. Sternic
BELGRADE, SERBIA

O2210  17:45  Refractory chronic cluster headache: A consensus statement on clinical definition from the European Headache Federation
D. Mitsikostas1, L. Edvinsson2, R. Jensen3, Z. Katsarava4,
C. Lamp5, A. Negro6, V. Oispova7, K. Paemeleire8, A. Siva9,
D. Valade10, P. Martelletti16
1ATHENS, GREECE, 2LUND, SWEDEN, 3COPENHAGEN, DENMARK,
4ESSEN, GERMANY, 5LINZ, AUSTRIA, 6ROME, ITALY, 7MOSCOW,
RUSSIAN FEDERATION, 8GHENT, BELGIUM, 9ISTANBUL, TURKEY,
10PARIS, FRANCE

O2211  Abstract cancelled
SUNDAY, JUNE 21, 2015
16:45-18:15

ORAL SESSION
MOTOR NEURONE DISEASES

Chairpersons:
Reinhard Dengler, HANNOVER, GERMANY
Vincenzo Silani, MILAN, ITALY

O2212
HFE p.His63Asp polymorphism is not a modifier of ALS phenotype
16:45
1TURIN, 2ROME, 3SIENA, 4MANGONE, 5GENOA, 6MODENA, 7MILAN, 8CAGLIARI, 9NAPLES, 10MISTRETTA, 11BARI, 12ANCONA, 13BOLOGNA, ITALY, 14BETHESDA, USA

O2213
Structural MRI reveals distributed cortical thinning in patients with pure lower motor neuron disease variants
17:00
P. M. Ferraro1, F. Agosta1, E. G. Spinelli1, N. Riva1, P. Valsasina1, M. Copetti2, A. Chiò3, S. Iannaccone1, V. Silani1, A. Falini1, G. Comi1, M. Filippi1
1MILAN, 2SAN GIOVANNI ROTONDO, 3TURIN, ITALY

O2214
Amyotrophic Lateral Sclerosis in the Caribbean Island of Guadeloupe: a new focus of ALS associated with parkinsonism
17:15
S. Mécharles, C. Alecu, A. Lannuzel
POINTE-À-PITRE, FRANCE

O2215
Development of a human cell model of amyotrophic lateral sclerosis using induced pluripotent stem cells
17:30
M. Naumann, X. Lojewski, A. Storch, A. Hermann
DRESDEN, GERMANY

O2216
The frontotemporal syndrome of amyotrophic lateral sclerosis is associated with poor survival and reduced efficacy of noninvasive ventilation
17:45
J. Raaphorst1, R. Govaarts2, E. Beeldman2, M.-J. van Tol9, A. van der Kooi2, L. H. van den Berg4, M. Kampelmacher4, P. Wijksa3, M. Zijnen-Suyker5, N. Cobben6, B. Schmand2, R. de Haan2, M. de Visser2
1NIJMEGEN, 2AMSTERDAM, 3GRONINGEN, 4UTRECHT, 5ROTTERDAM, 6MAASTRICHT, THE NETHERLANDS

O2217
Altered cerebral functional connectivity in pre-symptomatic individuals at risk of ALS
18:00
R. Menke1, M. Proudfoot1, J. Wu1, P. Andersen3, K. Talbot1, M. Benatar2, M. Turner1
1OXFORD, UNITED KINGDOM, 2MIAMI, USA, 3UMEA, SWEDEN
**ORAL SESSION MS AND RELATED DISORDERS 3**

Chairpersons:
- Giancarlo Comi, MILAN, ITALY
- Aksel Siva, ISTANBUL, TURKEY

---

**O2218 16:45**

**Progressive multiple sclerosis: correlations between diffuse white matter inflammation, active plaque formation and low age indicate peripheral immune involvement in a subset of patients**

S. Bramow\(^1\), J.M. Frischer\(^2\), H. Lassmann\(^2\), H. Broholm\(^1\), C.F. Lucchinetti\(^3\), P.S. Sørensen\(^1\), H. Laursen\(^1\)

\(^1\)COPENHAGEN, DENMARK, \(^2\)VIENNA, AUSTRIA, \(^3\)ROCHESTER, MINNESOTA, USA

---

**O2219 17:00**

**Efficacy of rituximab in refractory neuromyelitis optica**

N. Collongues\(^1\), D. Brassat\(^2\), E. Maillart\(^3\), P. Labauge\(^4\), J.-C. Ouallet\(^5\), C. Carra Dalliere\(^6\), T. Moreau\(^7\), B. Bourre\(^8\), A.-C. Papeix\(^3\), B. Audouin\(^9\), B. Brochet\(^5\), S. Vukusic\(^10\), J. de Seze\(^11\), R. Marignier\(^12\)

\(^1\)STRASBOURG, \(^2\)TOULOUSE, \(^3\)PARIS, \(^4\)MONTPELLIER, \(^5\)BORDEAUX, \(^6\)MONTPELLIER, \(^7\)DOJON, \(^8\)ROUEN, \(^9\)MARSEILLES, \(^10\)LYONS, \(^11\)STRASBOURG, \(^12\)LYONS, FRANCE

---

**O2220 17:15**

**Microstructural thalamic and cortico-thalamic correlates of cognitive impairment in pediatric multiple sclerosis**

E. De Meo\(^1\), M.A. Rocca\(^1\), L. Moiola\(^1\), A. Ghezzi\(^2\), P. Veggiotti\(^3\), R. Capra\(^4\), M.P. Amato\(^5\), A. Fiorino\(^1\), L. Pippolo\(^2\), M.C. Pera\(^3\), G. Comi\(^1\), A. Folini\(^1\), M. Filippi\(^1\)

\(^1\)MILAN, \(^2\)GALLARATE, \(^3\)PAVIA, \(^4\)BRESCIA, \(^5\)FLORENCE, ITALY

---

**O2221 17:30**

**Cerebrospinal fluid lipocalin-2 levels are reduced in multiple sclerosis and correlate with putaminal iron accumulation**


GRAZ, AUSTRIA
Oral Session: MS and related disorders 3 (CONDT.)

Chairpersons:
Giancarlo Comi, MILAN, ITALY
Aksel Siva, ISTANBUL, TURKEY

O2222 17:45 Cognitive impairment predicts disability and progression in newly-diagnosed relapsing-remitting multiple sclerosis
M. Moccia1, R. Lanzillo1, R. Palladino1, T. Costabile1, C.V. Russo1, A. de Rosa1, A. Carotenuto1, G.T. Maniscalco1, V. Brescia Morra1, K.C.-M. Chang2
1NAPLES, ITALY, 2LONDON, UNITED KINGDOM

O2223 18:00 Epstein-Barr virus antibodies in serum and DNA load in saliva do not correlate with clinical or radiological disease activity in patients with early multiple sclerosis
R. Giess1, C. Pfuhl1, J. Behrens1, L. Rasche1, J. Würfel1, A. Brandt1, F. Pache1, E. Freitag1, N. Khalighy1, C. Otto2, J. Hofmann3, B. Eberspächer3, J. Bellmann-Strobl1, F. Paul1, K. Ruprecht1
1BERLIN, 2POTSDAM, 3BERLIN, GERMANY
ORAL SESSION
PERIPHERAL NERVE DISORDERS 2

Chairpersons:
Eduardo Nobile-Orazio, MILAN, ITALY
Guido Stoll, WUERZBURG, GERMANY

O2224 16:45 Transition from asymptomatic to symptomatic TTR-FAP: a descriptive analysis of 94 subjects from the THAOS registry
T. Coelho¹, D. Keohane², M. Sultan², S. Short³, M.-L. Ong²
¹PORTO, PORTUGAL, ²NEW YORK, ³SAN FRANCISCO, USA

O2225 17:00 Diagnostic utility of somatosensory evoked potentials in chronic polyradiculopathy without ENMG signs of demyelination
P. Devic, P. Petiot, F. Mauguière
LYONS, FRANCE

O2226 17:15 The natural history of HSJ1-RELATED hereditary neuropathies: a case series of 9 patients with long-term follow-up
M. Frasquet Carrera¹, J.J. Vilchez¹, C. Marquez Infante², M.J. Chumillas¹, R. Sivera³, J. Vázquez-Costa¹, F. Palau¹, C. Espinos¹, T. Sevilla¹
¹VALENCIA, ²SEVILLE, ³GANDIA, SPAIN

O2227 17:30 Prognostic factors affecting long-term disability in multifocal motor neuropathy (MMN)
G. Galassi¹, A. Ariatti¹, F. Girolami², M. Tondelli¹, F. Benuzzi¹, F. Valzania¹, R. D’amico¹, S. Balduzzi², P. Nichelli¹
¹MODENA, ITALY, ²MANTUA, ITALY

O2228 17:45 The ultrasound pattern score – UPS: a new method to differentiate acute and subacute neuropathies using ultrasound of the peripheral nerves
A. Grimm¹, B. Décard¹, H. Axer²
¹BASEL, SWITZERLAND, ²JENA, GERMANY

O2229 18:00 Corneal confocal microscopy detects small-fibre damage, particularly in patients with sensory and autonomic ISFN
S. Javed¹, G. Ponirakis², M. Ferdousi¹, S. Azmi¹, I. Petropoulos², M. Tavakoli¹, M. Jeziorska¹, D. Gosai³, R.A. Malik²
¹MANCHESTER, UNITED KINGDOM, ²DOHA, QATAR, ³SALFORD, UNITED KINGDOM
TEACHING COURSE 7
NOVEL INSIGHTS IN STROKE AETIOLOGIES – LEVEL 3

Chairperson:
Franz Fazekas, GRAZ, AUSTRIA

Extra and intracranial arterial dissection
Stephanie Debette, PARIS, FRANCE

Vasculitis
Ruth Geraldes, LISBON, PORTUGAL

Cryptogenic stroke
Cristina Tiu, BUCHAREST, ROMANIA

Amyloid angiopathy
Franz Fazekas, GRAZ, AUSTRIA

The past years have seen a rapid progress in understanding, diagnosing and managing more rare but nonetheless critical causes and conditions of stroke. Thus for long cervical artery dissection appears to have been an underestimated cause of stroke especially in the young and we have first data from a randomized trial comparing different therapeutic strategies once this diagnosis has been established. Vasculitis remains a vexing problem and we have to take every effort not to miss out on this diagnosis but also not to overdiagnose it. There is an increasing number of tools available to reduce the number of cryptogenic stroke and the decision what to use when and for whom is not always easy. Finally cerebral amyloid angiopathy is much more prevalent than previously thought and may present quite variably. All that in focus this teaching course will provide insights that deepen our pathophysiologic understanding, show directions of future research and add to our competence in stroke management.
Epidemiological data speak for a marked increase in the incidence of multiple sclerosis (MS). Based on the recent update of the McDonald criteria, diagnosis of MS can already be made after the first relapse when magnetic resonance imaging gives evidence for dissemination in time. Yet at the same time, the challenges for diagnosis have increased: there must be clear evidence that no other inflammatory or metabolic disease of the central nervous system mimics MS. In this course, we will systematically discuss para-clinical methods, which can further differentiate MS from other diseases. Examinations of cerebrospinal fluid, magnetic resonance imaging, but also electrophysiological methods are the mainstay for further corroborating the diagnosis of MS. Finally, clinical vignettes will be presented.
Mitochondrial disorders are a particularly complex and heterogeneous group of disorders. Mutations in mitochondrial DNA or in nuclear mitochondrial genes lead to a plethora of multisystemic disorders that may literally manifest with any symptom, in any organ, and at any age. Apart from these classical inherited mitochondrial diseases, age-associated neurodegeneration as in Parkinson’s and Alzheimer’s disease as well as aging itself have been associated with mitochondrial dysfunction. This course will procure basic knowledge and new developments in mitochondrial medicine, from childhood disorders to aging, from pathomechanisms to therapy.
Immune-mediated white matter disorders occurring in the youngest age group comprise a heterogeneous group of diseases including acute disseminated encephalomyelitis (ADEM), multiple sclerosis (MS) and the spectrum of neuromyelitis optica disorders (NMO-SD). Newly described entities like myelin-oligodendrocyte-glycoprotein (MOG) antibody mediated disorders have further increased diagnostic and therapeutic challenges. Through case presentations and lectures, faculty will discuss those diverse childhood white matter diseases with emphasis on recently characterized syndromes and findings. Furthermore, the teaching course will provide an overview of MS-mimics, clues for diagnosis and treatment of ADEM and the most recent advances in the field of paediatric MS and cognition.
Neurological manifestations require rapid clinical, para-clinical and laboratory evaluation. In the last decade, imaging has assumed great importance in the assessment of these patients. However, the optimal approach to utilization of imaging for thorough and efficient care remains poorly defined for many neurologic presentations. Many courses provide an invaluable overview of the many important details of the pathology of neurologic disease. But patients present to the clinic with symptoms, which typically guide the clinician through a decision making process. This teaching course will therefore prioritize a symptom-based approach to imaging in neurologic diseases, based on the practice parameters developed by expert clinicians and imagers in the field. The approaches described in each lecture should provide a framework that can be utilized by the attendees to refine their approach, suggest alternative pathways, or encourage discussion that can result in more optimal clinical care.
Communication with patients in neurology is very often not easy. In this teaching course, we want to address difficult communication which is not due to neurological impairment but due to difficult contents. Frequently, we are not trained in breaking bad news, discussing end-of-life decisions and interventions or how to react if a patient asks for assisted dying. This course wants to address these issues in an interactive way with experienced colleagues from the field of neurology and palliative care.
SCIENTIFIC SATELLITE SYMPOSIUM AT CHARITÉ
EFNA-EAN PUBLIC AWARENESS DAY: UNDERSTANDING HEADACHE AND SLEEP DISORDERS

Location: Neurology Lecture Hall ("Hörsaal") in the "Alte Nervenklinik" at Charite Campus Mitte

15:00 Meet’n’greet
15:30 Welcome by Professor Wolfgang Oertel
Günther Deuschl, PRESIDENT, EUROPEAN ACADEMY OF NEUROLOGY
Audrey Craven, PRESIDENT, EUROPEAN FEDERATION OF NEUROLOGICAL ASSOCIATIONS

15:45 Diagnosing, Treating and Managing Headache and Sleep Disorders
Uwe Reuter, BERLIN, GERMANY
Claudia Trenkwalder, KASSEL, GERMANY

Followed by Questions and Answers

16:30 COFFEE BREAK

17:00 Patient Panel: Living with Headache and Sleep Disorders
Chaired by David Vodušek (chair EAN Liaison committee, SLOVENIA)

Including Questions and Answers
Patient Participants: Jakob Terhaag, cluster headache patient and Hartmut Stoye, Restless Legs Patient

17:35 The Future for Patients with Headache and Sleep Disorders
Wolfgang Oertel (coordinator of EAN sub-committee on European Affairs)

Followed by Questions and Answers

18:00 Closing words
ECNR European Congress of NeuroRehabilitation 2015

Vienna

December 1-4, 2015
Hofburg Congress Center
Vienna, Austria

Abstract Submission Deadline:
Tuesday, June 30, 2015 (12:00 CET)

www.ecnr.org
9th Congress of the
EUROPEAN PAIN FEDERATION
EFIC®

PAIN IN EUROPE IX

VIENNA, AUSTRIA, 2-5 SEPTEMBER 2015
TRANSLATING EVIDENCE INTO PRACTICE

REGISTER NOW AND SAVE
EARLY RATE DEADLINE: 6 MAY, 2015
HANDS-ON COURSE 4
NEUROPHYSIOLOGY III – ADVANCED

Chairperson:
Joseph Classen, LEIPZIG, GERMANY

Transcranial magnetic stimulation (TMS) – diagnostic applications
Joseph Classen, LEIPZIG, GERMANY

Therapeutic applications of neurophysiology. Non-invasive brain stimulation with repetitive TMS and transcranial direct current stimulation
Letizia Leocani, MILAN, ITALY

Sponsor?
Sold out!
SYMPOSIUM 4: PRECLINICAL ALZHEIMER'S DISEASE

Chairpersons:
Philip Scheltens, AMSTERDAM, THE NETHERLANDS
Reinhold Schmidt, GRAZ, AUSTRIA

Terminology and current criteria
Reinhold Schmidt, GRAZ, AUSTRIA

Validation status of "established" biomarkers for preclinical diagnosis
Philip Scheltens, AMSTERDAM, THE NETHERLANDS

New biomarkers
Markus Otto, GERMANY

Treatment in the pipeline
Christoph Hock, SCHLIEREN, SWITZERLAND
SYMPOSIUM 5: EXPANDING FIELDS IN NEUROLOGY

Chairpersons:
Michael Brainin, KREMS, AUSTRIA
David Vadušek, LJUBLJANA, SLOVENIA

Neurogeriatrics
Walter Maetzler, TÜBINGERN, GERMANY

Neurorehabilitation
Stéphanie Clarke, LAUSANNE, SWITZERLAND

Neuro intensive care unit: post-resuscitation
Maxwell Damian, CAMBRIDGE, UK

Neurology at the emergency room: stroke mimics
Atte Meretoja, HUS, FINLAND
SYMPOSIUM 6: PRESENT AND FUTURE TREATMENT IN MOVEMENT DISORDERS

Chairpersons:
Olivier Rascol, TOULOUSE, FRANCE
Kailash Bhatia, LONDON, UK

New therapies in Parkinson’s disease
Olivier Rascol, TOULOUSE, FRANCE

New therapeutic strategies in Huntington’s disease
Sarah Tabrizi, LONDON, UK

Current and future possibilities in the management of dystonia
Alberto Albanese, MILAN, ITALY

New treatments for ataxias
Thomas Klockgether, BONN, GERMANY
Known protein-coding genes compose less than 3% of the human genome. In contrast, a universe of non-coding RNAs, a heterogeneous population comprising long, short (100–300 nucleotides) and small (20–30 nucleotides) transcripts emerged as a major product of the genome. MicroRNAs (miRNA), a small non-coding RNA, post-transcriptionally regulate gene expression. Approximately over 60% of protein-coding gene expression is regulated by miRNAs and methods of miRNA manipulation emerge as potential therapeutic venues. These areas of research create an exciting field addressing the role of non-coding RNA in multiple sclerosis (MS) and identify an intriguing target for potential pharmacological intervention.
In this focused workshop the participants will learn
1. To discuss the physiological basis of rehabilitation of hand and locomotor function after stroke
2. To understand the role of neuroplasticity in supporting recovery of function
3. To understand the rationale behind novel neurorehabilitation approaches including drugs and non-invasive brain stimulation
4. To appreciate the range of novel technologies to support functional training
5. To consider limitations in the recovery of function after stroke
6. To explore the role of early prediction of outcome after stroke in stratification of appropriate training approaches
FOCUSED WORKSHOP 19
NON-PHARMACOLOGICAL ISSUES IN DEMENTIA

Chairperson:
Dorota Religa, STOCKHOLM, SWEDEN

1. Assess and interpret common cognitive and behavioural problems seen in patients affected by dementia and other neurological disorders with cognitive deficits
2. Support neurologists in the utilization of available tests for evaluation of fitness to drive in dementia
3. Present the risks, benefits and appropriate tests that are currently on the markets for cognitive stimulation and rehabilitation

Minimal requirements for driving. Regulations across European countries
Dorota Religa, STOCKHOLM, SWEDEN

Driving errors, accidents and their predictors in patients with cognitive disorders
Sokratis Papageorgiou, ATHENS, GREECE

What is the evidence for effect of cognitive stimulation in dementia?
Ana Catarina Santos, LISBON, PORTUGAL
Incidence of infections of the central nervous system is changing due to influence by environmental factors including climate changes and agricultural developments, as well human behaviour – migration and tourism –, and vaccination. This workshop will give an update on developments in occurrence of neuroinfections. Developments in vaccination activities have changed the profile of incidence of neuroinfections. Climatic changes have caused broadening of areas and seasons of arthropode-borne diseases, resulting in increasing number of cases. High mobility of people migrating and visiting foreign countries has posed a risk of infections, thus immunisation for vaccine-preventable diseases is essential for travellers.
Leukodystrophies are chronic progressive inherited white matter diseases frequently combined with an inborn error of metabolism. Better understanding of leukodystrophies in neurological routine practice is of crucial importance in the differentiation from other white matter diseases like toxic, inflammatory or vascular leukoencephalopathies. Many leukodystrophies are particularly important to recognize because specific treatments already exist or are currently under investigation. Using clinical, neurophysiological and MRI criteria adult-onset leukodystrophies can be delineated more precisely, facilitating diagnostic confirmation by genetic testing.
FOCUSED WORKSHOP 22
ANTIBODIES IN NEUROPATHY

Chairperson:
Simon Rinaldi, GLASGOW, UK

The glycolipid landscape of neural membranes: redefining the target for neuropathy-associated autoantibodies
Simon Rinaldi, OXFORD, UK

Autoantibodies to proteins in the nodal complex in inflammatory neuropathy
Isabel Illa, BARCELONA, SPAIN

Neuropathy-associated autoantibodies and their intracellular and membrane antigens in systemic diseases and cancer
Jean-Philippe Camdessanché, ST-ETIENNE, FRANCE

In this focused workshop the participants will learn
1. To gain an understanding of the different classes of neuropathy associated antibodies.
2. To review the range of anti-glycolipid antibodies and their clinical associations.
3. To appreciate the impact of the glycolipid-glycolipid interactions and antigen turnover on antibody binding and pathogenicity.
4. To review the functional anatomy of the nodal complex with respect to neuropathy associated antibodies.
5. To understand the evidence supporting a key pathological role for the nodal complex in inflammatory neuropathies.
6. To recognise the association between cancer, antibodies and peripheral nervous system pathology.
7. To appreciate the significance of intracellular versus membrane bound antigen targets.
Klaus Toyka will talk about the MG variant with IgG antibodies to MuSK, show the deleterious consequences of cholinesterase inhibitors in a mouse model warning against long-term pyridostigmine and discuss currently available treatments.

Nils Gilhus will discuss the optimal treatment of ocular MG, both to avoid generalization and minimize the ocular weakness. The diagnosis of ocular MG remains a challenge in some patients with negative antibody testing.

Jan Verschuuren will discuss the recent developments in the use of novel biological agents and small molecules in the treatment of MG. Several T cell receptors, B cell surface molecules, and complement or cytokine receptors are studied as possible new targets for a more efficacious and specific therapy for autoimmune MG.
INTERACTIVE SESSION 3
MOVEMENT AND GAIT DISORDERS

Chairperson:
Dominic Paviour, LONDON, UK

Video session and case presentations
This course encompasses the major bedside and auxiliary tests for evaluating patients with vestibular signs and symptoms. A room rotating scheme has been designed with four stations, spending twenty minutes at each, with practical demonstrations. The benign paroxysmal positional vertigo (BPPV) and neuro-otological bedside test stations will involve the neuro-otological clinical examination and the treatment of BPPV with the different manoeuvres for each separate canal BPPV. The vestibular evoked myogenic potential station will use a common evoked potential system available in all neurophysiological laboratories. The head impulse station will demonstrate head mounted video systems commercially available for eye movement documentation.

Sold out!
What have we learned about Parkinson’s disease from neurosurgery?
Andres Lozano, TORONTO, CANADA

Tony Marsdon Award
TOURNAMENT I HALL A3

MONDAY, JUNE 22, 2015

SPECIAL SESSION I HALL A3

BERLIN, GERMANY, 20 – 23 JUNE, 2015

T3101
14:45
The metabolic correlates of cognitive Impairment in amyotrophic lateral sclerosis: a 18F-FDG-PET study
A. Canosa1, M. Paganì2, A. Calvo1, F.M. Nobili3, S.D. Morbelli3, S. Cammarosana1, A. Montuschi1, B. Iazzolino1, A. Cistaro1, A. Chio1
1TURIN, 2ROME, 3GENOA, ITALY

T3102
15:00
Pain manifestations in an MPTP-induced rat model of Parkinson’s disease
A. Ciobica, R. Lefter, M. Paulet, V. Bild, M. Luca, D. Timofte
IASI, ROMANIA

T3103
15:15
Longitudinal DMN changes in cognitively preserved MS patients
NAPLES, ITALY

T3104
15:30
Phosphorylated alpha-synuclein in dermal nerve fibers of patients with multiple system atrophy
K. Doppler1, J. Weis1, K. Karl1, S. Ebert2, J. Ebentheuer2, C. Trenkwalder2, S. Klebe1, J. Volkman1, C. Sommer1
1WURZBURG, 2KASSEL, GERMANY

T3105
15:45
New insights on the pathophysiology of fatigue in MS: a fMRI study of the motor network
MILAN, ITALY

T3106
16:00
Cerebral hemodynamics show different patterns between patients with obstructive sleep apnea and periodic limb movement sleep syndrome during nocturnal sleep
Z. Zhang, M. Laures, G. Hügli, M. Qi, R. Khatami
BARMELWEID, SWITZERLAND

TOURNAMENT BASIC

Chairpersons:
Antonio Federico, SIENA, ITALY
Gustave Moonen, CHARNEUX-HERVE, BELGIUM
Guido Stoll, WUERZBURG, GERMANY

T3101
14:45
The metabolic correlates of cognitive Impairment in amyotrophic lateral sclerosis: a 18F-FDG-PET study
A. Canosa1, M. Paganì2, A. Calvo1, F.M. Nobili3, S.D. Morbelli3, S. Cammarosana1, A. Montuschi1, B. Iazzolino1, A. Cistaro1, A. Chio1
1TURIN, 2ROME, 3GENOA, ITALY

T3102
15:00
Pain manifestations in an MPTP-induced rat model of Parkinson’s disease
A. Ciobica, R. Lefter, M. Paulet, V. Bild, M. Luca, D. Timofte
IASI, ROMANIA

T3103
15:15
Longitudinal DMN changes in cognitively preserved MS patients
NAPLES, ITALY

T3104
15:30
Phosphorylated alpha-synuclein in dermal nerve fibers of patients with multiple system atrophy
K. Doppler1, J. Weis1, K. Karl1, S. Ebert2, J. Ebentheuer2, C. Trenkwalder2, S. Klebe1, J. Volkman1, C. Sommer1
1WURZBURG, 2KASSEL, GERMANY

T3105
15:45
New insights on the pathophysiology of fatigue in MS: a fMRI study of the motor network
MILAN, ITALY

T3106
16:00
Cerebral hemodynamics show different patterns between patients with obstructive sleep apnea and periodic limb movement sleep syndrome during nocturnal sleep
Z. Zhang, M. Laures, G. Hügli, M. Qi, R. Khatami
BARMELWEID, SWITZERLAND
ORAL SESSION I HALL A7

MONDAY, JUNE 22, 2015
14:45-16:15

ORAL SESSION
AGEING AND DEMENTIA

Chairpersons:
Ana Verdelho, LISBON, PORTUGAL
Gunhild Waldemar, COPENHAGEN, DENMARK

O3101
14:45
Grey and white matter MRI signatures of the frontotemporal lobar degeneration continuum
F. Agosta1, S. Galantucci1, G. Magnani1, A. Marcone1, D. Martinelli1, M.A. Volonte1, N. Riva1, S. Iannaccone1, P.M. Ferraro1, F. Caso1, A. Chio2, G. Comi1, A. Falini1, M. Filippi1
1MILAN, 2TURIN, ITALY

O3102
15:00
Alzheimer’s disease neurodegeneration markers in Alzheimer’s disease neuroimaging initiative
D. Andriuta1, V. Moullart1, S. Schraen2, M.-E. Meyer1, O. Godefroy1
1AMIENS, 2LILLE, FRANCE

O3103
15:15
Motor symptoms in healthy ageing and dementia: frequency, patterns and the relation between motor and cognitive functions
T. Bak1, G. Bennett2, A. Symonds1, M. Parra2, M. Elamin2, P. Connick2, G. Holloway2, S. Pal2
1EDINBURGH, 2EDINBURGH, UNITED KINGDOM

O3104
15:30
Effects of cardiovascular risk factors, dialysis and renal transplantation on plasma β-amyloid levels in chronic kidney disease: is there a contribution of renal dysfunction to neurodegeneration?
ESSEN, GERMANY

O3105
15:45
Effect of moderate-to-high intensity endurance exercise in elderly community-dwelling persons with mild-moderate Alzheimer’s disease
COPENHAGEN, DENMARK
MONDAY, JUNE 22, 2015

ORAL SESSION CEREBROVASCULAR DISEASES 2

Chairpersons:
Natan Bornstein, TEL AVIV, ISRAEL
Anna Czlonkowska, WARSAW, POLAND

O3106 14:45
Renal function, MRI brain changes and post-stroke cognitive impairment
N. Bornstein¹, E. Auriel¹, E. Kliper¹, S. Shenhar-Tsarfaty¹,
A. Mike¹, D. Ben-Bashat¹, L. Shopin², H. Hallevi¹,
A.D. Korczyn²
¹TEL-AVIV, ISRAEL, ²TEL AVIV, ISRAEL

O3107 15:00
Influence of age and co-morbidities on the safety and efficacy of novel platelet inhibitors in acute ischemic stroke in mice
P. Kraft, M. Schuhmann, G. Stoll, B. Nieswandt, A. Zernecke,
C. Kleinschnitz
WÜRZBURG, GERMANY

O3108 15:15
Predictors of new onset atrial fibrillation after an ischemic stroke.
C. Sabben, C. Guidoux, L. Sissani, P. Lavallée,
D. Messika Zeitoun, P.G. Steg, P. Amarenco
PARIS, FRANCE

O3109 15:30
Lack of response to conventional glucose management in acute ischemic stroke patients and stroke outcome. The GLIAS-2 study
B. Fuentes Gimeno¹, B.E. Sanz Cuesta¹,
P. Martinez Sánchez¹, R. Delgado Medeiros², J. Gallego³,
M. Blanco⁴, M.T. Martinez Zabaleta⁵,
M.D.M. Freijó Guerrero⁶, M. Alonso De Leciñana¹,
J.C. Portilla⁷, A. Gil Nuñez¹, E. Diez Tejedor¹
¹MADRID, SPAIN, ²BARCELONA, SPAIN, ³NAVARRA, SPAIN,
⁴SANTIAGO DE COMPOSTELA, SPAIN, ⁵SAN SEBASTIAN, SPAIN,
⁶BILBAO, SPAIN, ⁷CÁCERES, SPAIN

O3110 15:45
Surveillance for atrial fibrillation in patients with cryptogenic stroke using an implantable loop recorder in a community hospital setting: real world validation of Crystal AF
A. Seiler, J. Allred, S. Biby, P. Sethi
GREENSBORO, USA

O3111 16:00
Concomitant headache in acute ischaemic stroke: relation with CT angiography and CT perfusion characteristics
H. van Os¹, I. Mulder¹, M. van Walderveen¹,
I. van der Schaaf², J. Kappelle², M. Ferrari¹, A. Algra²,
M. Wermer¹
¹LEIDEN, ²UTRECHT, THE NETHERLANDS
ORAL SESSION COGNITIVE NEUROLOGY

Chairpersons:
Frederik Barkhof, AMSTERDAM, THE NETHERLANDS
Stefano F. Cappa, MILAN, ITALY

O3112 14:45 Connected speech production in the nonfluent variant of primary progressive aphasia and its relationship with white matter damage
E. Canu, F. Agosta, S. Galantucci, E. Catricalà, P.M. Ferraro, G. Magnani, A. Marcone, G. Comi, A. Falini, M. Filippi
MILAN, ITALY

O3113 15:00 Spontaneous eye movements in Parkinson's disease correlate with default mode network functional connectivity
M. Gorges, H.-P. Müller, A.C. Ludolph, E.H. Pinkhardt, J. Kassubek
ULM, GERMANY

O3114 15:15 Transcranial direct current stimulation in language disorders in semantic primary progressive aphasia: "Towards a rational therapy in degenerative diseases of language"
C. Lesoil, J. Godard, M. Teichmann, A. Valero-Cabre, M. Vernet, R. Levy, B. Dubois
PARIS, FRANCE

O3115 15:30 Randomized controlled trial on hemifield eye patching and optokinetic stimulation in acute spatial neglect
B. Machner, I. Koenemund, A. Sprenger, J. von der Gablentz, C. Helmchen
LÜBECK, GERMANY

O3116 15:45 Discourse impairment in early Alzheimer's disease may reflect memory retrieval difficulties rather than lexical ones
A. Pistono, M. Jucla, E. Barbeau, L. Saint-Aubert, M. Puel, J. Pariente
TOULOUSE, FRANCE

O3117 16:00 Cognitive functions in multiple system atrophy and progressive supranuclear palsy
S. Skelina, R. Pavlova, M. Petrova, S. Mehrabian, L.D. Traykov
SOFIA, BULGARIA
ORAL SESSION NEUROIMAGING

Chairpersons:
Jacques De Reuck, GHENT, BELGIUM

O3118 14:45 Regional white matter abnormalities and cognitive impairment in MS: a multicenter TBSS study
A. Bisecco1, M.A. Rocca1, E. Pagani1, O. Ciccarelli2, C. Enzinger3, A. Gallo4, H. Vrenken5, M.L. Stromillo6, T.A. Yousry2, F. Fazekas3, G. Tedeschi4, F. Barkhof5, N. De Stefano6, M. Filippi1
1MILAN, ITALY, 2LONDON, UNITED KINGDOM, 3GRAZ, AUSTRIA, 4NAPLES, ITALY, 5AMSTERDAM, THE NETHERLANDS, 6SIENA, ITALY

O3119 15:00 Multimodal TMS/EEG, FDG-PET and active fMRI assessments in patients with disorders of consciousness and locked-in syndrome.
O. Bodart1, S. Wannez1, A. Thibaut1, J. Annen1, A.G. Casali2, S. Casarotto3, M. Rosanova3, O. Gosses4, M. Massimini1, S. Laureys1
1LIEGE, BELGIUM, 2SAO PAULO, BRAZIL, 3 MILAN, ITALY, 4 MADISON, USA

J.L. De Reuck
LILLE, FRANCE

O3121 15:30 Multicenter analysis of the structural connectome in Amyotrophic Lateral Sclerosis in >250 patients
H.-P. Müller1, S. Abrahams2, P. Bede3, M. Filippi4, V. Govind5, J. Grosskreutz6, J. Prudlo7, M.R. Turner8, J. Kassubek1, M. Gorges1, The Neuroimaging Society in ALS (NiSALS) DTI Study Group1
1ULM, GERMANY, 2EDINBURGH, UNITED KINGDOM, 3DUBLIN, IRELAND, 4 MILAN, ITALY, 5MIAMI, USA, 6 JENA, GERMANY, 7ROSTOCK, GERMANY, 8OXFORD, UNITED KINGDOM

O3122 15:45 Processing face encoding in multiple sclerosis: an fMRI investigation
MILAN, ITALY

O3123 16:00 White matter and cortical degeneration in progressive supranuclear palsy
S. Zanigni, S. Evangelisti, D.N. Manners, G. Calandra-Buonaura, L. Sambati, M. Guarino, A. Gabellini, P. Cortelli, R. Lodi, C. Tonon
BOLOGNA, ITALY
ORAL SESSION
CEREBROVASCULAR DISEASES 3

Chairpersons:
José Ferro, LISBON, PORTUGAL
Didier Leys, LILLE, FRANCE

O3201 16:45  Age and “rich club” status affect the vulnerability of the structural connectome to stroke: a study of simulated lesions in older adults
R. Berlot¹, M. O’Sullivan²
¹LJUBLJANA, SLOVENIA, ²LONDON, UNITED KINGDOM

O3202 17:00  Occurrence of early seizures in patients with non-traumatic spontaneous intracerebral hemorrhage may improve the survival
T. Bruening¹, M. Al-Khaled²
¹HAMBURG, ²LÜBECK, GERMANY

O3203 17:15  Seizure burden in patients with subarachnoid hemorrhage: association with functional and cognitive outcome at 3 months
G.M. De Marchis¹, D. Pugin², E. Meyers³, A. Velasquez³,
S. Park³, M.C. Falo³, S. Agarwal³, S. Mayer³,
J.M. Schmidt³, E.S. Connolly³, J. Claassen³
¹BASEL, SWITZERLAND, ²GENEVA, SWITZERLAND, ³NEW YORK, USA

O3204 17:30  Predictors of unruptured cerebral aneurysms in patients with headache: findings from the Nationwide Inpatient Sample (NIS) 2011 Database
N. Jadeja, A. Ramesh, K. Nalleballe, P. Mabie, L. Ocava
NEW YORK, USA

O3205 17:45  Depressive symptoms following stroke and TIA: is it Time for a more intensive treatment approach? results from the TABASCO cohort study
O. Tene, S. Shenhar-Tsarfaty, A.D. Korczyn, E. Kliper,
H. Hallevi, L. Shopin, E. Auriel, A. Mike, N. Bornstein,
E. Ben Assayag
TEL AVIV, ISRAEL

O3206 18:00  Effect of intravenous thrombolysis on stroke patients with atrial fibrillation treated in Lille (France) and Belgrade (Serbia)
V. Padjen¹, M. Bodenant², D. Jovanovic¹,
N. Ponchelle-Dequatre², C. Cordonnier², I. Berisavac¹,
M. Ercegovac¹, P.D. Stanarcevic¹, M. Stefanovic Budimic¹,
L. Beslac Bumbasirevic¹, D. Leys²
¹BELGRADE, SERBIA, ²LILLE, FRANCE
ORAL SESSION
MUSCLE AND NEUROMUSCULAR JUNCTION DISEASE

Chairpersons:
Nils Erik Gilhus, BERGEN, NORWAY
Angela Vincent, OXFORD, UNITED KINGDOM

O3207  16:45  Geographical distribution of myasthenia gravis
M. Boldingh1, A. Maniaol1, C. Brunborg1, L. Dekker2, A.T. Heldal2, A.F. Lipka2, T.H. Popperud1, E.H. Niks2, J.J. Verschuuren2, C. Tallaksen1
1OSLO, NORWAY, 2LEIDEN, THE NETHERLANDS, 3BERGEN, NORWAY

O3208  17:00  Evaluation of dysphagia in inclusion body myositis by novel real-time MRI
GOTTINGEN, GERMANY

O3209  17:15  Genetics of myasthenia gravis: a case control genetic association study in Han Chinese population
H. Li1, Y. Hong2
1JINAN, CHINA, 2BERGEN, NORWAY

O3210  17:30  Long-term follow-up of patients with dystrophin deficiency and isolated hyperckemia
VALENCIA, SPAIN

O3211  17:45  Severe myotonia in myotonic dystrophy type 2 caused by CLCN1 or SCN4A mutations acting as modifying factors
G. Meola1, E. Bugiardini1, R. Cardani1, A. Botta2, G. Rossi2, I. Merli1, B. Fossati1
1SAN DONATO MILANESE (MI), 2ROME, ITALY

O3212  18:00  Intracranial arterial abnormalities in patients with late onset Pompe’s disease (LOPD)
F. Montagnese, F. Granata, O. Musumeci, C. Rodolico, M. Longo, A. Toscano
MESSINA, ITALY
Auto-antibodies against contactin-1 in patients with inflammatory neuropathy

L. Appeltshauser¹, K. Doppler¹, C. Villmann¹, H. Krämer², M. Maurer³, S. Dib-Hajj⁴, S. Waxman⁴, A. Weishaupt¹, C. Sommer¹

¹WÜRZBURG, ²GIESSEN, ³BAD MERGENTHEIM, GERMANY, ⁴NEW HAVEN, USA

Paraneoplastic neurological syndromes associated with antibodies against glutamic acid decarboxylase

H. Ariño¹, R. Höftberger¹, E. Martínez-Hernández¹, T. Armangué¹, M. Kruer², J. Arpa³, J. Domingo³, B. Rojc⁴, L. Bataller⁵, A. Saiz¹, J. Domingo³, B. Rojc⁴, L. Bataller⁵, A. Saiz¹, J. Domingo³, B. Rojc⁴, L. Bataller⁵

¹BARCELONA, SPAIN, ²SOUTH DAKOTA, USA, ³MADRID, SPAIN, ⁴IZOLA, SLOVENIA, ⁵VALENCIA, SPAIN, ⁶PHILADELPHIA, USA

Immune cell brain-derived neurotrophic factor (BDNF) expression is associated with thalamic volume and third ventricle enlargement in neurolupus patients

A. Kalinowska-Lyszczarz, M. Pawlak, S. Michalak, K. Pawlak-Buś, P. Leszczynski, M. Puszczewicz, W. Paprzycki, W. Kozubski

POZNAN, POLAND

Stability of cognitive functions in MS patients treated with fingolimod over one year


ERLANGEN, GERMANY

Clinical spectrum of patients with possible autoimmune encephalopathy

J. Martins¹, A. Rua¹, A.P. Correia¹, R. Taipa², A. Martins Silva³, E.P. Coutinho³, E. Santos¹

¹PORTO, PORTUGAL, ²OXFORD, UNITED KINGDOM

Adherence and cognitive-behavioral performance in relapsing-remitting MS (RRMS) patients using the electronic autoinjector RetainSmart™: 1 year of follow-up from the German multicentre RETAINsmart study

H. Schreiber¹, J. Gössling², R. Hartmann³, K. Gehring⁴, K. Gößwein⁵, C. Bischoff⁶, M. Lang¹, S. Braune⁷, U. Fulda⁸, A. Bergmann⁵

¹ULM, ²BUCHHOLZ, ³ELTVILLE, ⁴ITZEHOE, ⁵NEUBURG, ⁶MUNICH, ⁷PRIEN, ⁸DARMSTADT, GERMANY
LATE BREAKING NEWS

Chairpersons:
Paul Boon, GHENT, BELGIUM
Franz Fazekas, GRAZ, AUSTRIA

L101  16:45  Self-management education for adults with poorly controlled epilepsy: the SMILE trial
L. Ridsdale
LONDON, UNITED KINGDOM

L102  17:00  Alemtuzumab decreases new lesion formation and slows the rate of brain atrophy in relapsing-remitting multiple sclerosis patients previously treated with subcutaneous interferon beta-1a
F. Barkhof1, A. Rovira2, T. Ziemssen3, D.H. Margolin4, L. Kasten4, D.L. Arnold5
1AMSTERDAM, THE NETHERLANDS, 2BARCELONA, SPAIN, 3DRESDEN, GERMANY, 4CAMBRIDGE, USA, 5MONTREAL, CANADA

L103  17:15  Current status of ISIS-TTRRx phase 3 study in patients with transthyretin familial amyloid polyneuropathy (FAP)
T. Coelho1, A. Martins Silva1, E. Ackermann2, M.M. Yamashita2, S. Hughes2, B. Monia2
1PORTO, PORTUGAL, 2CARLSBAD, USA
This course focuses on invasive treatments for Parkinson's disease including levodopa and apomorphine pump infusions and deep brain stimulation. The first lecture will provide participants with an overview of treatments for PD and the second lecture will focus on selecting patients for invasive therapies. Finally, the last two lectures will focus on the results of infusion clinical trials and DBS therapies specifically and present technique specific complexity in management and adverse events.
The ever-increasing number of therapeutic options now available in multiple sclerosis (MS) has transformed patient management but has also added a new layer of complexity. Utilising these treatments in an appropriate and effective manner requires a sound understanding of when and how they should be introduced informed by a comprehensive knowledge of their efficacy and their side-effect profile. This session describes an up to date understanding of our use of all the agents available to us in the treatment of MS, including the concept of first and second line treatments, symptomatic management and importantly the complex safety and side-effect profile.
When is the epilepsy truly medically refractory?
Reetta Kälviäinen, KUOPIO, FINLAND

Imaging of refractory epilepsy
Paul Hofman, MAASTRICHT, THE NETHERLANDS

Epilepsy syndromes amenable to epilepsy surgery
Martin Holtkamp, BERLIN, GERMANY

Neurostimulation strategies for epilepsy
Kristl Vonck, GHENT, BELGIUM
In neurological practice, patients with facial pain are regarded as difficult to diagnose and treat. The evidence for existing treatment strategies is very scarce or completely lacking. Many patients with suspected trigeminal neuralgia are referred directly to neurosurgery for invasive treatments with a risk of severe or lethal complications. The objective is to improve the diagnostic strategies, to optimize medical treatment and clinical decision-making, based on scientific evidence and specialist experience, and to raise scientific interest in facial pain.
The aim of neurological critical care is to provide, in a prompt fashion, acute medical therapies and appropriate interventions in neurological illnesses accompanied by CNS/PNS- and/or organ dysfunction. This Teaching Course will focus on major aspects of care for various neurological pathologies necessitating diagnostic and/or therapeutic neuro-critical care management. Starting from basic knowledge, the lectures concentrate on the latest guideline recommendations and expert’ opinions in each topic. At the end of the course the participants will be able to:

• assess the needs of nutrition, water and electrolyte intake, evaluate and provide adequate therapeutic approach in different clinical conditions
• understand the differential indications, mechanisms, benefits and risks of analgesia, sedation and relaxation and should be able to apply these modern techniques in NICU patients.
• know the indications, contraindications and risks of lumbar drainage and ventricular drainage in NICU patients

These lectures, offered in an interactive manner, should allow neurologists to manage these fundamental issues of critical patient care regardless of the administrative organization of the working unit.
Recently, a bidirectional relationship between sleep and neurological disorders has been demonstrated. Sleep disturbances are very common and often occur early in the course of neurological disorders, such as Parkinson disease and Alzheimer disease. Moreover, sleep disturbances may influence the course and outcome of neurological disorders. For example, sleep disordered breathing may affect cognition and worsen the outcome of stroke and epilepsy.

The objective of the course is to understand how to approach sleep problems in a neurological patient. The importance of a structured clinical interview will be explained and the sleep diagnostic tests will be presented. A part of the course will be dedicated to the pharmacological and non-pharmacological approaches of sleep disorders in neurology.
See you at ESOC 2016
10-12 May, Barcelona

The 2nd European Stroke Organisation Conference 2016

10-12 May, 2016
Barcelona, Spain

www.ESOC2016.com

Kenes International Organizers of Congresses S.A.
7, rue François-Versonnex, 1207 Geneva, Switzerland
Tel: +41 22 908 0488 | Fax: +41 22 906 9140
31st INTERNATIONAL EPILEPSY CONGRESS

ISTANBUL, TURKEY, 5-9 SEPTEMBER 2015

JOINTLY ORGANISED BY THE INTERNATIONAL LEAGUE AGAINST EPILEPSY AND THE INTERNATIONAL BUREAU FOR EPILEPSY

REGISTRATION – To facilitate registration of delegates, registration fees have been considerably reduced. In conjunction with this, members of an ILAE Chapter or an IBE Member Association get an additional discount.

WHY ATTEND?

- EARN CME accreditation
- LEARN about the most significant research developments in epilepsy
- MEET influential leaders from world leading epilepsy institutions
- NETWORK with many colleagues from around the world

For further information regarding all of the above, please visit www.epilepsyistanbul2015.org

REGISTER NOW!
SYMPOSIA I HALL A8

SYMPOSIUM 7
MULTIPLE SCLEROSIS THERAPY MOVING FORWARD/ WHERE IS THE TRUTH? HOPES AND HAZARDS

Chairpersons:
Hans-Peter Hartung, DÜSSELDORF, GERMANY
Catherine Lubetzki, PARIS, FRANCE

MS pathogenesis – where is it heading now?
Finn Sellebjerg, COPENHAGEN, DENMARK

Injectable first-line therapies in MS (INF & GA) – do they still have a place in MS therapy?
Ludwig Kappos, BASEL, SWITZERLAND

Current MS therapies
Hans-Peter Hartung, DÜSSELDORF, GERMANY

The future of MS therapies – how soon, how far? How effective, how safe?
Catherine Lubetzki, PARIS, FRANCE
SYMPOSIUM 8
INFECTIONS OF THE CENTRAL NERVOUS SYSTEM: RECENT ADVANCES

Chairpersons:
Erich Schmutzhard, INNSBRUCK, AUSTRIA
Israel Steiner, PETACH TIKVA, ISRAEL

New diagnostic techniques in central nervous system infections
Israel Steiner, PETACH TIKVA, ISRAEL

New antimicrobial therapeutics in community acquired and nosocomial meningitis and brain abscess
Diederik van de Beek, AMSTERDAM, THE NETHERLANDS

Adjunctive therapies in life-threatening CNS infections
Erich Schmutzhard, INNSBRUCK, AUSTRIA

News in prevention of CNS infections
Timo Vesikari, TAMPERE, FINLAND
MEDITERRANEAN SESSION – JOINTLY ORGANISED BY EAN AND PAUNS (PAN ARAB UNION OF NEUROLOGICAL SOCIETIES): POST-STROKE SEQUELAE

Chairpersons:
Mohammed S. El-Tamawy, LAIRO, EGYPT
Jean-Michel Vallat, LIMOGES, FRANCE

Post-stroke dementia
Riadh Gouider, TUNIS, TUNISIA

Post-stroke depression
Mohamed Ezzat Elwan, CAIRO, EGYPT

Stroke-related seizures
Jacques De Reuck, GHENT, BELGIUM

Post-stroke rehabilitation
Jozef Opara, TARNOWSKIE GÓRY, POLAND
HISTORY OF NEUROLOGY SESSION

Chairperson:
Axel Karenberg, COLOGNE, GERMANY

Interdependence of European and German neurology
Peter Koehler, HEERLEN, THE NETHERLANDS

Interdependence of European and World neurology
(the different schools: England, France, Spain, Germany - Japan, China, South America - foundation of the WFN - relation to WHO)
Francois Boller, WASHINGTON, USA
EAYNT (EUROPEAN ASSOCIATION OF YOUNG NEUROLOGISTS AND TRAINEES):
From study design to clinical practice and EBN neurology exam

Chairperson:
TBA

About study designs
Maurizio A. Leone

Lost in translation, how to apply research in clinical practice
Speaker: TBC

EBN neurology examination
Jan Kuks, XXX

Update on movement disorders
Speaker: TBC
TUESDAY, JUNE 23, 2015

10:30-12:15

HIGHLIGHTS OF THE CONGRESS & CLOSING SESSION

Chairperson:
Matthias Endres, BERLIN, GERMANY
Günther Deuschl, KIEL, GERMANY (TBC)

Andrew Chan, BOCHUM, GERMANY
Richard Dodel, MARBURG, GERMANY
Oliver Kastrup, ESSEN, GERMANY
Christoph Kleinschnitz, WÜRZBURG, GERMANY
Felix Rosenow, MARBURG, GERMANY
Claudia Sommer, WÜRZBURG, GERMANY
Lars Timmermann, KÖLN, GERMANY

After the presentation of the Congress Highlights the winners of the Tournament Prizes will be announced and receive their certificates. Afterwards there will be a short introduction to the upcoming congress and the host city Copenhagen 2016. Closing words by Günther Deuschl, EAN President.
Auto-antibodies cause various neurological conditions, which could present movement disorders as prominent feature. It is important to recognize and diagnose the underlying disorders because they can be treated and dramatically improve patient outcomes. This teaching course will focus on paraneoplastic and Paediatric Autoimmune Neuropsychiatric Disorders (PANDAS) as well as disorders that are associated with NMDA, voltage gated, antiphospholipid and other auto-antibodies. The final presentation will be a clinical review and approach to autoimmune movement disorders that will include take-away messages for clinicians who may encounter these patients in their clinical practice.
TEACHING COURSE 20
CLINICAL AND THERAPEUTICAL APPROACH TO MUSCLE DISORDERS – LEVEL 1

Chairperson:
Corrado Angelini, PADOVA, ITALY

Fatigue and exercise intolerance
Antonio Toscano, MESSINA, ITALY

Antibodies and clinical outcome in neuromuscular diseases
Nils Erik Gilhus, BERGEN, NORWAY

When to perform a muscle biopsy in muscle pain, cramps or hyperCKemia
Corrado Angelini, PADOVA, ITALY

Therapeutic approaches to muscle diseases
Marianne de Visser, AMSTERDAM, THE NETHERLANDS

This teaching course is for the general neurologist and diverse groups of professionals to inform them how to deal with biomarkers and clinical presentation of neuromuscular disorders. This course will introduce the problem of biomarkers, such as antibodies and CK. These serum biomarkers will indicate, according to international guidelines, when to perform muscle biopsy and how they correlate with the course of the disease. The problem of exercise intolerance and fatigue will be analysed and therapy approaches to neuromuscular disorders will be presented. The course attendee will be able to correlate clinical presentation with both diagnostic issues and treatment.
A formal neurological history taking and bedside examination form the basis of the neurological diagnosis. Only then ancillary tests can be ordered in a logical way. The course provides essential facts about the examination starting with cranial nerves, motor and sensory system including proper reflex testing, and lastly neuropsychology and higher cortical functions. Functional or psychogenic neurological symptoms are one of the commonest reasons for patients to seek help from a neurologist. Basic skills and special examination techniques in functional disorders will be covered that allow neurologists to make a positive confident diagnosis.
Use and misuse of screening tools and assessment questionnaires for neuropathic pain
Didier Bouhassira, BOULOGNE-BILLANCOURT, FRANCE

What is the place of standard neurological examination and quantitative sensory testing?
Per Hansson, STOCKHOLM, SWEDEN

What is the place of neurophysiological examination?
Giorgio Cruccu, ROMA, ITALY

Management of neuropathic pain
Claudia Sommer, WÜRZBURG, GERMANY

This teaching course will address various aspects of the management of neuropathic pain. First, we will discuss the interest and limitations, both in daily practice and clinical research, of a series of screening tools developed and validated over the last decade. Then, in addition to the standard bedside clinical examination, the contribution for the assessment of the patients of other methods and technics, such as quantitative sensory testing and electrophysiology, will be addressed. Finally, an update about the treatment strategies of these chronic pain syndromes will be presented.
Update on chronic daily headache management
Peter Sandor, BADEN, SWITZERLAND

New treatment in restless legs
Diego Garcia Borreguero, MADRID, SPAIN

Managing of acute neuroletravioural changes
Niruj Agranoud, LONDON, UK

Transcranial stimulation (TMS, DC)
Walter Paulus, GÖTTINGEN, GERMANY
“Typical” Alzheimer’s disease (AD) is defined clinically by an onset characterised by progressive episodic memory dysfunction, reflecting pathological involvement of medial temporal lobe structures. It is now widely recognized that different clinical presentations may actually be associated with the pathological hallmarks of AD. These include progressive disorders of language, fulfilling the criteria for primary progressive aphasia, progressive visuo-spatial dysfunction (described as the posterior cortical atrophy syndrome), and progressive disorders of executive function and behaviour (possibly reflecting prominent prefrontal involvement). Familiarity with these “atypical” phenotypes is crucial in cognitive neurology, not only because they are diagnostically challenging, but also because they may provide important insights into AD pathogenesis.
How advanced neuroimaging is improving diagnosis and monitoring of gliomas
Riccardo Soffietti, TURIN, ITALY

Update on diagnosis and treatment of primary CNS lymphomas
Uwe Schlegel, BOCHUM, GERMANY

Metastatic complications of systemic cancer
Wolfgang Grisold, VIENNA, AUSTRIA

Non-metastatic complications of systemic cancer
Jérôme Honnorat, LYON, FRANCE

The aim of the TC is to give an update on a wide spectrum of neuro-oncologic topics in whom clinical neurologists are frequently involved.

R. Soffietti will discuss the usefulness of advanced MRI (MRS, perfusion, DTI) and PET with amino-acids techniques for differential diagnosis and treatment monitoring of gliomas after conventional and anti-angiogenic agents.

U. Schlegel will discuss two major issues in the management of PCNSL: how to improve the outcome with more aggressive and specific therapies. How to better spare the normal brain from the damage from therapies?

W. Grisold will update on the modern approach to brain, leptomeningeal and spinal metastases.

J. Honnorat will illustrate the large number of infectious, metabolic, paraneoplastic and treatment-related complications of systemic cancer.
The Lancet Neurology is the leading clinical neurology journal, delivering essential original research, expert review, and candid commentary to provide context and perspective on today’s clinical advances. Publishing only the highest quality clinical content, we are committed to its rapid dissemination with Fast Track online publication within 8 weeks of submission. With an Impact Factor of 21.823, we rank first among all clinical neurology journals.

Gain greater insight and stay well-informed with The Lancet Neurology’s resources:

- High impact research and reviews
- Expert commentary and breaking news
- Free eToC and news alerts
- Free podcasts featuring renowned authors
- Specially commissioned Series and reports, many of which are freely available
- Newly relaunched! The Lancet iPad app with unlimited 24/7 access
SATELLITE SYMPOSIA
20th International Congress of Parkinson’s Disease and Movement Disorders

JUNE 19-23, 2016
BERLIN, GERMANY

Save the Date
www.mdscongress2016.org

International Parkinson and Movement Disorder Society
BIOGEN: A MULTIPLE SCLEROSIS PATIENT JOURNEY: WHAT DRIVES DECISIONS?

Chairperson:
David Bates, NEWCASTLE UPON TYNE, UK

Prognosis at onset: charting a course
Mar Tintoré, BARCELONA, SPAIN

Selecting treatment, SETTING GOALS: GUIDING THE WAY
Sven Meuth, MÜNSTER, GERMANY

Vigilant monitoring: compass bearings
Jens Wuerfel, BERLIN, GERMANY

Evidence informing treatment sequencing: Navigating change
James Overell, GLASGOW, UK

An exploration of patient management, engaging faculty in commentary and discussion throughout
UCB: THE HIPPOCRATIC OATH “DO NO HARM” – CONSIDERATIONS FOR THE LONG-TERM TREATMENT OF CHRONIC NEUROLOGICAL DISEASES

Chairperson:
Paul A.J.M. Boon, GHENT, BELGIUM

Enzyme induction: just a matter of managing drug-drug interaction
Martin J. Brodie, GLASGOW, UNITED KINGDOM

Practical considerations for treatment decisions in new or recently diagnosed epilepsy patients
Philippe Ryvlin, LYON, FRANCE

Benefit of early therapy for long-term outcome in Parkinson’s disease
Lars Timmermann, COLOGNE, GERMANY
DR. WILLMAR SCHWABE: EXPECTATIONS MANAGEMENT FOR NEUROCOGNITIVE DISORDERS PATIENTS

Chairperson:
Ralph Ihl, KREFELD, GERMANY

Treatment options in mild neurocognitive disorders patients
Reto Kressig, BASEL, SWITZERLAND

Treatment management in major neurocognitive disorders
Serge Gauthier, VERDUN, CANADA
NOVARTIS: MS IN THE REAL WORLD

Chairperson:
Judith Haas, BERLIN, GERMANY

Increasing the evidence base: importance of imaging measures
Sven Schippling, ZÜRICH, SWITZERLAND

Brain volume loss and its role in evolving clinical outcome measures
Björn Tackenberg, MARBURG, GERMANY

Importance of real-world data collection for physicians and patients
Tjalf Ziemssen, DRESDEN, GERMANY

Summary and close
Judith Haas, BERLIN, GERMANY
NOVARTIS: THE UNSOLVED MYSTERY OF MS: EVOLVING THE TREATMENT PARADIGM TO IMPROVE PATIENT OUTCOMES

Chairperson:
Heinz Wiendl, MÜNSTER, GERMANY

The first clues: treating early to impact disease activity
Bernd Kieseier, DÜSSELDORF, GERMANY

Collecting the evidence: measuring brain volume loss in clinical practice
Eva Havrdová, PRAGUE, CZECH REPUBLIC

Accumulating evidence: brain volume loss and long-term disability
Maria Pia Sormani, GENOA, ITALY

Building the case: impacting patient outcomes across four measures of disease activity
Jaume Sastre-Garriga, BARCELONA, SPAIN

Summary and close
Heinz Wiendl, MÜNSTER, GERMANY
BRITANNIA: NON ORAL DRUG DELIVERY STRATEGIES; FROM EARLY DIAGNOSIS TO ADVANCED TREATMENTS

Chairpersons:
Claudia Trenkwalder, KASSEL, GERMANY
Werner Poewe, INNSBRUCK, AUSTRIA

Gastrointestinal dysfunction in Parkinson's disease
Werner Poewe, INNSBRUCK, AUSTRIA

Wearing off and delayed on – motor and non-motor fluctuations
Fabrizio Stocchi, ROME, ITALY

Apomorphine Penject - AMIMPAKT trial results and best clinical practice
Stuart Isaacson, MIAMI, UNITED STATES
ACTELION: A NEW AGE IN DETECTION, DIAGNOSIS AND DISEASE MANAGEMENT: FUNDAMENTAL PROGRESS IN NIEMANN PICK DISEASE TYPE C

Chairperson:
Paul Gissen, LONDON, UNITED KINGDOM

Diagnostic difficulties: the broad spectrum of symptoms in NP-C
Paul Gissen, LONDON, UNITED KINGDOM

Frequently overlooked signs: oculomotor abnormalities in NP-C
Michael Leo Strupp, MUNICH, GERMANY

The hunt for NP-C: ataxia as a key neurological sign
Mathieu Anheim, STRASBOURG, FRANCE

Identifying and managing neurological disorders: lessons from adults with NP-C
Jordi Gascon Bayarri, BARCELONA, SPAIN

Q & A
GENZYME: SUSPICIOUS MINDS – WHY, WHERE AND HOW TO LOOK FOR FABRY’S AND POMPE’S DISEASE IN THE NEUROLOGY SETTING

Chairperson:
Max Josef Hilz, ERLANGEN, GERMANY

Early diagnosis and treatment of Fabry’s disease
Max Josef Hilz, ERLANGEN, GERMANY

Could this patient with a stroke be a Fabry’s disease patient?
Alessandro P. Burlina, BASSANO DEL GRAPPA, ITALY

Clinical and therapeutic clues in the management of Pompe’s disease
Antonio Toscano, MESSINA, ITALY

Could it be Pompe’s disease? How to not get caught in a diagnostic trap
Cornelia Kornblum, BONN, GERMANY
TEVA: BREAKING DOWN THE WALLS IN MULTIPLE SCLEROSIS?

Chairperson:
Tjalf Ziemssen, DRESDEN, GERMANY

Working out the challenges faced by MS patients and neurologists
Mar Tintoré, BARCELONA, SPAIN
Gavin Giovannoni, LONDON, UNITED KINGDOM

Bringing new therapies to people with MS: the case of Copaxone 40mg tiw
Peter Rieckmann, BAMBERG, GERMANY

Cop 40mg tiw in the real world
Daniel Wynn, UNITED STATES

The future treatment of neurodegenerative diseases
Michael Hayden, PETAH TIKVA, ISRAEL
TAKEDA: POST-STROKE COGNITIVE IMPAIRMENT: CHALLENGES AND NEW TREATMENT STRATEGIES

Chairperson:
Alla Guekht, MOSCOW, RUSSIAN FEDERATION

Problems and current status of post-stroke cognitive impairment (PSCI)
Amos D. Korczyn, TEL AVIV, ISRAEL

Treatment challenges of PSCI
Antonio Federico, SIENA, ITALY

Prevention of PSCI: ARTEMIDA study results
Alla Guekht, MOSCOW, RUSSIAN FEDERATION
EISAI: GENERALISED SEIZURES: CHALLENGES AND SOLUTIONS

Chairperson:
Christian Elger, BONN, GERMANY

Burden of illness
- TBA

How to diagnose IGE?
- TBA

Treatment options and challenges
- TBA

What’s new?
- TBA
BIAL: COMT INHIBITION IN PARKINSON’S DISEASE: PAST REFLECTIONS, FUTURE DIRECTIONS

Chairperson:
Andrew J. Lees, LONDON, UNITED KINGDOM

The science of the COMT inhibitor
Olivier Rascol, TOULOUSE, FRANCE

The COMT inhibitor story so far
Werner Poewe, INNSBRUCK, AUSTRIA

Pipeline development
Joaquim José Coutinho Ferreira, LISBON, PORTUGAL
GENZYME: FROM MOA TO CLINICAL TREATMENT DECISIONS. IS THERE A NEW WAY OF THINKING IN MS?

Chairperson:
Nikolaos Grigoriadis, THESSALONIKI, GREECE

T & B cells in MS immunopathology – What’s one without the other?
Nikolaos Grigoriadis, THESSALONIKI, GREECE

Targeting T & B cells to optimize MS treatment strategies
Finn Thorup Sellebjerg, COPENHAGEN, DENMARK
Volker Limmroth, COLOGNE, GERMANY

Q & A
Nikolaos Grigoriadis, THESSALONIKI, GREECE
ZAMBON: CHANGING THE TREATMENT PARADIGM IN MID- TO LATE-STAGE PD: EXTENDING STABILITY IN PARKINSON'S DISEASE

Chairpersons:
Heinz Reichmann, DRESDEN, GERMANY
Paolo Barone, NAPLES, ITALY

Unmet needs in mid- to late-stage PD: pathophysiological and treatment insights
Paolo Barone, NAPLES, ITALY

Dopaminergic and non-dopaminergic targets in PD treatment: the dual mechanism of action of safinamide
Ruggero Fariello, BASEL, SWITZERLAND

Counteracting the dopaminergic/glutamatergic imbalance in PD: clinical efficacy and tolerability of safinamide
Heinz Reichmann, DRESDEN, GERMANY

Interactive patient case series: treatment challenges in mid- to late-stage PD
Werner Poewe, INNSBRUCK, AUSTRIA
EISAI: OPTIMIZING EPILEPSY THERAPY
- SEARCHING FOR THE EVIDENCE, LOOKING BEYOND THE DATA

Chairperson:
Mar Carreño, BARCELONA, SPAIN

Safety of old and new antiepileptic drugs – better the devil we know?
Eugen Trinka, SALZBURG, AUSTRIA

Efficacy of old and new AEDs – are they all the same?
Martin Holtkamp, BERLIN, GERMANY

How to choose the right AED for my patient – evidence-based or empiric decision?
Round table discussion
PFIZER: TTR-FAP (TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY): A RARE AND FATAL POLYNEUROPATHY REQUIRING EARLY DIAGNOSIS

Chairpersons:
Ernst-Fritz Hund, HEIDELBERG, GERMANY
Giampaolo Merlini, PAVIA, ITALY

The early diagnosis of TTR-FAP – why it is essential?
Giampaolo Merlini, PAVIA, ITALY

Working together to achieve an early diagnosis of TTR-FAP
Yesim Parman, ISTANBUL - CAPA, TURKEY

The benefits of an early diagnosis and treatment of TTR-FAP
Isabel Maria Santos Conceicao, LISBON, PORTUGAL
HOFFMANN-LA ROCHE: BACK TO BASICS IN NEUROIMMUNOLOGY: WHAT EVERY NEUROLOGIST NEEDS TO KNOW AND WHY!

Chairpersons:
Eva Havrdova, PRAGUE, CZECH REPUBLIC
Bernhard Hemmer, GERMANY

The ABC of Neuroimmunology
Gavin Giovannoni, LONDON, UNITED KINGDOM

T-cells in neurology and MS: still the leader?
Bernhard Hemmer, GERMANY

B-cells in neurology and MS: the renaissance?
Edgar Meinl, MUNICH, GERMANY

Neuroimmunology in context: MS today and in the future!
Olaf Stuve, DALLAS, TX, UNITED STATES

Panel discussion & audience Q+A
Eva Havrdova, PRAGUE, CZECH REPUBLIC
**TTR-FAP**: a rare and fatal polyneuropathy requiring early diagnosis

*TTR-FAP: Transthyretin Familial Amyloid Polyneuropathy*

Monday June 22nd 2015
13.00–14.30
Hall A4, CityCube

**Co-Chairmen:**
Professor Ernst Hund *(University of Heidelberg, Germany)*
Professor Giampaolo Merlini *(University of Pavia, Italy)*

**Agenda**

13.00  Welcome and introduction
       Professor Ernst Hund, University of Heidelberg, Germany

13.10  The early diagnosis of TTR-FAP – why it is essential
       Professor Giampaolo Merlini, University of Pavia, Italy

13.30  Working together to achieve an early diagnosis of TTR-FAP
       Professor Yeşim Parman, Istanbul Faculty of Medicine, Istanbul, Turkey

13.50  The benefits of an early diagnosis and treatment of TTR-FAP
       Dr. Isabel Conceição, Centro Hospitalar Lisboa Norte-Hospital de Santa Maria, Lisbon, Portugal

14.10  Panel discussion

14.25  Co-Chairmen’s close